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Abstract 
Introduction 
Doxorubicin (DOX) is an effective treatment against a variety of cancers, and thus remains a 
commonly used chemotherapeutic drug. The chief side effect of DOX treatment is 
cardiotoxicity. The precise mechanisms by which DOX induces cardiotoxicity are unknown. 
One of the most accepted mechanisms is the excess production of ROS. The structure of DOX 
allows it to undergo redox cycling and form DOX-iron complexes, both of which generate free 
radicals. DOX-induced oxidative damage is more prevalent in the heart than other organs. As 
the pathogenesis of cardiotoxicity appears to be mediated by oxidative stress, it seems as if the 
most effective treatment would be antioxidant therapy. Antioxidant therapy has proved 
unsuccessful. Autophagy is a catabolic process which allows a cell to remove cytoplasmic 
components. Components regarded as surplus or defective may be removed to ensure the 
survival of the cell. There have been numerous studies conducted to evaluate the relationship 
between DOX and autophagy. Many of these studies have concluded that DOX treatment does 
affect autophagy. Although there is literature to support both the up and downregulation of 
autophagy. We hypothesis that during the development of DOX-induced cardiotoxicity 
autophagy is downregulated. Attenuation of this downregulation during DOX therapy will 
attenuate the effects of cardiotoxicity. 
Methodology 
Three-week-old male black 6 (C57BL/6) mice were split into six groups; vehicle control, DOX, 
rapamycin, a starvation, DOX and rapamycin combination and DOX and starvation group. The 
DOX group received 2mg/kg DOX weekly for a total of eight weeks, resulting in a cumulative 
dose of 16mg/kg.  The rapamycin group received 2mg/kg rapamycin weekly. The DOX and 
rapamycin group received rapamycin 30 minutes prior to receiving DOX. The starvation group 
was starved from food for 24 hours each week but were allowed free access to drinking water. 
The DOX and starvation group were starved for 24 hours prior to receiving DOX. A week after 
the final treatment, mice were euthanised. The whole hearts were harvested and sectioned, 
roughly into halves. One half of each was stored in formaldehyde solution for histological 
analysis, the other was frozen in liquid nitrogen for biochemical analysis. H&E staining was 
performed to assess tissue morphology and cardiomyocytes area. Picrosirius red staining was 
performed to assess fibrosis. Fluorometry was done to assess oxidative stress via GSH, GSSG 
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and CDs levels. Western blots were performed to assess expression of caspase 3 and LC3. A 
Kolmogorov- Smirnov normality test was done to test for a normal distribution. Appropriate 
statistical tests were applied. P-values were considered significant when P < 0.05. 
Results 
Differences in body mass first appeared at week 5, with both DOX+ Rapa and DOX+ starve 
weighing less than control. Differences then appeared (at week 6) between DOX and control, 
with DOX weighing less than control. These differences continued until the end of the study. 
Histology showed cardiomyocyte area was decrease in the DOX group (97.4± 4.1) the control 
(112.6± 4.3). There was also an increase in fibrosis in the DOX group (2.07± 0.22) compared 
to the control (1.05± 0.18) and the DOX+ starve group (1.21± 0.18) had less fibrosis than DOX 
alone. Biochemical analysis showed autophagy was decreased in the DOX group (0.3733± 
0.0683) compared to the control group (1.1420± 0.2262). However, the DOX+ Rapa (0.4344± 
0,0543) and DOX+ starve (0.4818± 0.1240) groups also had decreased autophagy compared to 
the control group. 
Discussion 
The histological analysis confirms cardiotoxicity as DOX caused cardiac damage. Biochemical 
analysis was less straightforward. Oxidative stress markers were tested for too long after levels 
may have been detectable. While this provides no oxidative stress data, it suggests the 
cardiotoxicity was chronic rather than acute, as cardiac damage persisted after the stress had 
ended. Apoptotic data was inconclusive. DOX treatment caused a decrease in autophagy. 
Meaning, as hypothesised, this could be the target of an adjuvant therapy. The adjuvant 
treatment groups showed some improvement when compared to the DOX group. Both the 
DOX+ Rapa and DOX+ starve group showed histological improvement. The LC3 data 
however showed, the adjuvant therapies did not upregulate autophagy. Neither DOX+ Rapa 
nor DOX+ starve showed any increases in autophagy when compared to DOX. Due to the lack 
of attenuation of autophagic dysregulation, the reason for the protective effect of the adjuvant 
therapy is a mystery. Regardless, this study suggests that autophagic upregulation a potential 
adjuvant therapy. 
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Uittreksel 
 
Inleiding  
Doksorubisien (DOX) dien as ‘n effektiewe behandelingsmiddel in onkologie en sodoende ‘n 
fundamentele chemoterapeutiese middel wat teen ‘n verskeidenheid kankers gebruik word. Die 
kliniese gebruik hiervan word beperk deur die kumulatiewe dosis afhangklike newe effekte 
wat maande, jare en selfs dekades na behandeling aanleiding kan gee tot die ontstaan van 
hartversaking.  Daar word voorgestel dat kardiotoksisiteit, wat die hoof newe effek is wat met 
doksorubisien toediening geassosieer word, gerig is op oormatige ROS produksie wat ‘n 
toestand van oksidatiewe stres veroorsaak en gevolglik seldood as ‘n afstroom effek 
veroorsaak.  Dit is verder bekend dat die chemiese struktuur van DOX betrokke is in 
resirkulering en die vorming van DOX-yster komplekse wat beide vryradikale kan produseer.  
Omrede die hart energie moet produseer om aan sy funksionering te kan voldoen in hierdie hoë 
oksidatiewe omgewing met lae anti-oksidant beskerming, word regenerasie kapasiteit 
ingeperk. Dit is dus verstaanbaar hoekom hierdie orgaan vatbaar is vir oksidatiewe stress.  
Hoewel kardiotoksisiteit geklassifiseer kan word as akute- en chronies stadium, is daar 
beperkte behandelingsopsies of ondersteuningsterapie om hierdie vertraging van newe effekte 
te voorkom.  Outofagie, ‘n evolusionêre konserveringsproses van proteïendegradasie, het 
voorheen in verskeie kardiovaskulêre patologieë beskerming getoon.  Daar is ook verskeie 
teenstrydige bewyse in die literatuur oor die rol van DOX en outofagtiese aktiwiteit; dit is nie 
duidelik of die onaktiewiteit daarvan bydra tot kardiotoksisiteit en/of die aktiwiteit beskerming 
bied nie.  Hierdie studie ondersoek dus die potensiële beskermings effekte van outofagiese 
opregulering in ‘n rotmodel met verlengde DOX behandeling.   
Metodologie: 
Nadat etiese goedkeuring vir die studie verleen is, is drie week oue manlike swart 6 (C57BL/6) 
muise ontvang en ewekansig verdeel in ses eksperimentele groepe na klimatisering. Hierdie 
groepe sluit in: ‘n kontrole (draer), rapamisien, uithongering, DOX en kombinasies van DOX 
met rapamisien of uithongering. Terwyl die DOX en rapamisien groepe 2 mg/kg DOX of 
rapamisien weekliks ontvang het, is die uithongeringsgroep 24 uur weerhou van voedsel. In 
die kombineringsgroep is rapamisien 30 minute voor DOX behandeling toegedien, wat vooraf 
met ‘n 24 uur uithongeringsperiode vooraf gegaan is voordat chemoterapeutiese behandeling 
begin is. Die behandelingsprotokol is vir agtweke volhou met alle toedienings intraperitoneaal 
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gelewer.  Een week na die finale toediening is die muise met behulp van eutanasie dood gemaak 
waarna die harte verwyder is. Een helfte van die hart is in formaldehiedoplossing vir 
histologiese evaluasie geberg, en die ander helfte gevries in vloeibare stikstofvir biochemiese 
analises. Om die morfologiese wysigings te ondersoek asook ontwikkeling van fibrose is ‘n 
H&E en Picrosirius rooikleuring uitgevoer. Anti-okisdant status en oksidatiewe skade is bepaal 
deur veranderinge in die gereduseerde versus geokssideerde glutatioonverhouding en die 
teenwoordigheid van gekonjugeerde diëene onderskeidelik. Ten slotte is apoptose bepaal deur 
die uitdrukking van kaspase-3 vlakke. Gepaste statistiese toetse is gebruik waar p < 0.05 as 
betekenisvol beskou is. 
Resultate 
Verskille in die liggaamsmassa is beduidend teen die vyfde week met DOX behandeling en die 
outofagiese opregulering het geen bydrae gelewer tot hierdie verlies aan massa nie.  Geen 
verandering in miokardiale massa is waargeneem by enige van die behandelingsgroepe nie.  
Daar is wel betekenisvolle fibrose (2.07±0.22%, p < 0.001) met ‘n afname in miobrillêre area 
(97.41±4.1 M2, p < 0.01) in die DOX behandelings groepe versus die kontrole (1.05 ±0.18% 
fibrose, 112.6 ±4.32 M2) opgemerk. Vergeleke met die DOX groep, het die 
kombineringsgroep verlaagde fibrose in uithongering getoon (1.21±0.18%, p < 0.01) en ‘n 
matige toename in miofibrillêre area is waargeneem. Verbasend is daar geen veranderinge 
waargeneem in die oksidatiewe stresparameters en induksie van apoptose nie.  Hierdie studie 
het suskesvol demonstreer dat DOX ‘n kragtige inhiberings effek op outofagie het omrede 
beide intervensies wat gebruik is om die aktiwiteit te stimuleer onsuksesvol was om hierdie 
toestand te handhaaf in die teenwoordigheid van DOX. 
Bespreking 
Hierdie studie het die terapeutiese potensiaal van verhoogde outofagie deur farmakologiese 
(rapamisien) en ‘n fisiologiese (uithongering) benadering ondersoek in ‘n poging om die newe 
effekte wat met DOX terapie in die hart geassosiëer word te verlaag. Hoewel die model wat 
hier gebruik is uniek is en wel sekere eienskappe vertoon het, hoofsaaklik fisies 
(liggaamsmassa) en struktureel (miofibrillêre area en fibrose); het die biochemiese parameters 
(oksidatiewe stres en apoptose) onoortuigende resultate opgelewer.  Hoewel die resultate van 
ons studie veronderstel dat strukturele modifikasies aanvang neem voordat biochemiese 
veranderinge onstaan, kan daar geen defnitiewe afleidings gemaak word oor die die impak van 
terapeutiese intervensie in hierdie scenario nie.   
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Chapter 1: Literature Review 
1.1. Anthracycline chemotherapy 
Anthracycline antibiotics are a class of chemotherapeutic antibiotics, first isolated from 
Streptomyces cultures in the late 1950s in laboratories across the globe (Muggia & Green 
1991). Doxorubicin (DOX), an anthracycline first isolated in the early 1960s from 
Streptomyces peucetius bacteria, is an effective treatment against a variety of cancers, listed in 
Table 1.1 (Arcamone et al. 1969; Tacar et al. 2012). Due to its effectiveness DOX remains a 
commonly used chemotherapeutic drug and is even listed by the World Health Organisation 
(WHO) on their model list of essential medicines (Tacar et al. 2012; World Health Organization 
2017). 
1.2. Anti-cancer Mechanisms of action 
Despite its wide use, the precise mechanisms of action of DOX’s chemotherapeutic effects are 
still under debate. There have been several proposed mechanisms, each with merit. Some of 
the proposed mechanisms include the generation of free radicals, the inhibition of deoxyribose 
nucleic acid (DNA) synthesis and direct membrane binding. Free radical generation results in 
increased oxidative stress, causing the induction of lipid peroxidation as well as DNA damage 
(Keizer et al. 1990). DNA synthesis is inhibited by the formation of DOX-DNA adducts, the 
disruption of DNA unwinding, strand separation, helicase and topoisomerase II activities and 
transcription (Goodman et al, 1974; Gewirtz, 1999; Cutts et al, 2005). 
Of the many proposed mechanisms, the two most probable appear to be the generation of free 
radicals and the inhibition of topoisomerase II activity. These two mechanisms are the most 
cited and relevant, not only in the context of cancer therapy but also in the context of 
cardiovascular disease (Keizer et al, 1990; Ghigo et al, 2015). 
 Table 1.1: Table listing DOX treated cancers, adapted from Tacar et al, 2012 
Adrenal cortex cancer Multiple myeloma 
Bone cancer Pancreatic cancer 
Breast cancer Prostate cancer 
Cervical, endometrial, uterine and womb cancer Skin, mucous membrane cancer 
Head and neck cancer Soft tissue cancer e.g. leiomyosarcoma  
Lung cancer  Stomach cancer 
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1.2.1.1. Redox cycling 
The structure of DOX allows it to act as an electron acceptor and thus undergoes redox cycling 
to generate free radicals (Goodman et al, 1974). Structurally, as indicated in Figure 1.1 A, DOX 
has aglyconic and sugar moieties. The tetracyclic ring makes up the aglyconic moiety and the 
sugar moiety, attached at carbon (C)-7, consists of a 3-amino-2,3,6- trideoxy-L-fucosyl moiety 
called daunosamine. This unique feature is understood to be responsible for antineoplastic and 
cardiotoxic effects. There is a methoxy substituent at C-4. Quinone groups are present on C-5 
and C-12 and hydroquinone groups are present on C-6 and C-11 respectively. Finally, a 
primary alcohol side chain located at C-9 differentiates DOX from other anthracyclines. A 
carbonyl is present at C-13. (Minotti et al, 2004). 
Reduction of the quinone groups on the C ring, catalysed by nicotinamide adenine dinucleotide 
(NADH), nicotinamide adenine dinucleotide phosphate (NADPH) or cytochrome P-450 
reductase, converts the quinones to semiquinone free radicals. These semiquinone free radicals 
are then oxidised by donating an electron to oxygen (O2), thus generating superoxide anions 
(O2-) and other reactive oxygen species (ROS) such as hydrogen peroxide (H2O2). This 
reaction, indicated in Figure 1.1 B is cyclic and can generate large amounts of free radicals. 
(Keizer et al, 1990; Minotti et al, 2004). 
 
 
Figure 1.1 A: Diagram displaying the structure of DOX. B: Redox cycling of the quinone groups on the C 
ring, converting quinones to semiquinone free radicals. Semiquinone free radicals are oxidised by 
donating an electron to 02, generating 02- and H202. Adapted from Minotti et al, 2004 
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1.2.2. Iron complexes 
DOX also forms free radicals through the reduction of DOX-iron complexes. The two main 
mechanisms of DOX-iron complex free radical formation are indicated in Figure 1.2, one 
dependent (Figure 1.2 red) and one independent of a reducing system (Figure 1.2 green). 
In the presence of a reducing system, DOX-iron(III) (DOX-Fe3+) complex is reduced to DOX-
iron(II) (DOX-Fe2+) (by NADPH or cytochrome P-450 reductase or glutathione). DOX-Fe2+ is 
then oxidised by donating an electron to O2. As with the redox cycling previously described, 
this reaction is cyclic and generates ROS (Zweier, 1984). H2O2 can react with DOX-Fe
2+ to 
form hydroxyl radicals (OH). 
In the absence of a reducing system DOX-Fe3+ can reduce chelated iron by two separate 
intramolecular redox reactions. Either by oxidation of the hydroquinone moiety at ring B or 
the oxidation of the C-9 side chain. This forms the DOX-Fe2+ complex which is oxidized to 
generate free radicals. Further oxidation of the C-9 side chain leads to the formation of the 
oxidized metabolite of DOX, 9-dehydroxyacetyl-9-carboxyl doxorubicin (9-COOH- 
doxorubicin) (Zweier et al, 1986). This leads to DNA damage, lipid peroxidation and 
ultimately destruction of the cell (Muindi et al, 1984; Keizer et al, 1990).  
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1.2.3. Topoisomerase II 
Another widely supported mechanism of action for DOX is its ability inhibit topoisomerase II 
(Top2) activity. Top2 is an enzyme consisting of alpha (α) and beta (β) isoforms. Both isoforms 
are present in mammalian cells and are essential for cell replication. During DNA replication 
Top2 induces double strand breaks and then covalently binds proteins to the broken ends to 
prevent rearrangement or illicit a DNA damage response. This mechanism helps uncoil the 
DNA, allowing replication to take place. Following DNA replication, Top2 also assists in 
chromatid condensation and prevents early chromatid separation during mitosis. Additionally, 
Top2 assists in transcription activation. Cell machinery monitors the activity of Top2 and uses 
its various functions as checkpoints to monitor the cell cycle and allow replication to take place. 
Defective functioning of Top2 would be detected by the cell machinery and lead to the 
destruction of the defective cell (Nitiss, 2009).  
Figure 1.2: Iron complex free radical formation in the presence of a reducing system, DOX-Fe3+ 
complex is reduced to DOX-Fe2+, then oxidised by donating an electron to 02, H202 also reacts with 
DOX-Fe2+ to form OH (red). In the absence of a reducing system, DOX-Fe3+ can reduce its chelated iron 
by two redox reactions, oxidation of the hydro-quinone moiety at ring B or the oxidation of the C9 
side chain. This forms the DOX-Fe2+ which is oxidized to generate free radicals. Oxidation of the C9 
side chain leads to the formation of the oxidized metabolite of DOX, 9-COOH-doxorubicin (green). 
Adapted from Keizer et al, 1990. 
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DOX inhibits Top2 function by forming a stable Top2-DNA complex. The two central B and 
C rings of DOX overlap with adjacent DNA base pairs and the D ring passes through the 
intercalation site of the Top2-DNA complex forming a stable adduct. This DOX-Top2-DNA 
complex is formed after the double strand break and thus prevents DNA from resealing thus 
eliciting a DNA damage response which leads to apoptosis (Tewey et al, 1984; Minotti et al, 
2004). 
1.3. Cardiotoxicity 
Like many medications, DOX has unwanted side effects, chief of which is cardiotoxicity 
(Lefrak et al, 1973). Cardiotoxicity is a broad term used to define any toxicity that affects the 
heart. This definition, however, is vague and may apply to any toxin affecting the heart. This 
had led to some debate about whether certain cardiac pathologies may be linked to 
chemotherapy. Subsequently, chemotherapy-induced cardiotoxicity has been clinically defined 
by the cardiac review and evaluation committee supervising trastuzumab (breast cancer 
chemotherapeutic) clinical trials. According to this committee chemotherapy-induced 
cardiotoxicity is defined as one or more of the following; 
• signs or symptoms of heart failure (HF) 
• a reduction in left ventricular ejection fraction (LVEF) globally or in the 
interventricular septum specifically 
• a reduction in LVEF between 5% and 55% in the presence of signs or symptoms of HF 
• a reduction in LVEF between 10% and 55% in the absence signs or symptoms of HF 
(Seidman et al, 2002; Florescu et al, 2013). 
There is evidence, dating back to the late 1970s, to support a dose-response relationship 
between DOX and the increased risk of cardiotoxicity (Von Hoff et al, 1979). This study found 
a 3% risk of cardiotoxicity at a cumulative dose of 400 mg/m², 7% at 550 mg/m² and 18% at 
700 mg/m². Thus, it was concluded to limit DOX to a cumulative dose of less than 550 mg/m². 
However, while this number is still considered by many to be the upper limit for DOX 
exposure, subsequent studies have suggested this limit to be much lower. Swain et al, 2003 
found that the risk of developing cardiotoxicity to be 5% at 400 mg/m², 26% at 550 mg/m² and 
48% at 700 mg/m². Based on these estimates it was suggested to further reduced the limit of 
DOX to a cumulative dose of no more than 400 mg/m². The difference is most likely due to the 
unclear definition of DOX-induced cardiotoxicity and more specifically, the numerous risk 
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factors associated with the increased risk of developing cardiotoxicity such as age, gender, 
underlying cardiovascular abnormalities or previous chemotherapeutic treatment. This 
underlines the need for stricter definitions, standards and guidelines. Regardless, while limiting 
the dose of DOX reduces the risk of cardiotoxicity, it is not completely effective at preventing 
this pathology as cardiotoxicity may still develop even at lower doses. Patients suffering from 
DOX-induced cardiotoxicity are broadly classified into two types; acute or chronic. 
1.3.1. Acute cardiotoxicity  
The acute form of cardiotoxicity, associated with cardiomyocyte dysfunction, develops either 
during treatment or a few hours/days thereafter. There are a wide variety of symptoms 
including; electrocardiograph (ECG) changes (particularly ST-T changes) and cardiac 
arrhythmias (particularly sinus tachycardia). Inflammatory responses such as pericarditis or 
myocarditis do occur although they are less common. This form of cardiotoxicity is clinically 
manageable and is dose-independent. Treatment of the individual symptoms tends to resolve 
the condition without lasting damage (Lefrak et al, 1973; Bristow et al, 1978; Frishman et al, 
1996; Florescu et al, 2013). 
1.3.2. Chronic cardiotoxicity 
The chronic form, associated with cardiomyocyte death, develops months or even years after 
treatment. There are a wide variety of physiological symptoms including atrophy, chamber 
dilation, fibrosis and overall functional decline, particularly of the left ventricle. This functional 
decline may progress to congestive heart failure and ultimately death (Frishman et al, 1996). 
Biopsies reveal histological damage including cardiac tissue containing cells with abnormal 
nuclei, severe mitochondrial damage, partial or complete myofibril loss (which leaves only 
remnants of peripheral Z disks) and vacuolar degeneration (characterised by swelling and 
merging of vacuoles). Unlike the acute form, there are currently no effective therapies to treat 
chronic cardiotoxicity, resulting in permanent damage (Takemura & Fujiwara, 2007; 
Vejpongsa & Yeh, 2014). 
In contrast to acute cardiotoxicity, chronic cardiotoxicity is does-dependent and causes 
irreversible damage to the myocardium. As such, there are currently no effective therapies to 
treat this condition, other than a heart transplant (Vejpongsa & Yeh, 2014). Since this condition 
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takes years to manifest, it is difficult to determine he main mechanisms involved, although a 
few have been proposed.  
1.3.3. Proposed mechanisms of cardiotoxicity 
The precise mechanisms of action for DOX-induced cardiotoxicity are unknown. One of the 
long-standing theories suggested to be responsible for DOX-induced cardiotoxicity is the 
oxidative stress hypothesis. This is due to the ability of DOX to generate elevated levels of free 
radicals (Olson et al, 1981), as previously mentioned. Furthermore, the heart is more 
susceptible to oxidative damage than other organs. 
As the myocardium is a muscle which is constantly active, it requires a great deal of energy. 
To cope with this high demand of adenosine triphosphate (ATP), cardiac tissue contains a 
greater number of mitochondria than most tissues. DOX is known to have a high affinity for 
cardiolipin, a phospholipid found in the inner mitochondrial membrane, binding and forming 
a strong complex with cardiolipin, resulting in accumulation of DOX in the mitochondria 
(Goormaghtigh et al, 1980). This accumulation of DOX in the mitochondria in turn leads to 
iron accumulation in the mitochondria. DOX reduces the levels of ATP-binding cassette sub-
family B member 8 (ABCB8), a protein which regulates mitochondrial iron export. It also 
increases mitochondrial ferritin, an iron storage protein. This prevents iron from exiting the 
mitochondria, causing it to build up within the organelle, leading to formation of ROS within 
the cardiac mitochondria through reduction of the quinone groups on the C ring and reduction 
of DOX-iron complexes, as previously mentioned. In addition, there is also a reduction of 
endothelial nitric oxide synthase (eNOS) and NADPH, although these contribute relatively 
small amount of ROS (Ichikawa et al, 2014). The localised increase in oxidative stress as well 
as the relatively low levels of antioxidants in the heart results in apoptosis of cardiomyocytes. 
Apoptosis is believed to be the cause of the severe damage associated with chronic 
cardiotoxicity (Octavia et al, 2012). 
1.3.4. The role of apoptosis 
Apoptosis is a form of programmed cell death. Carefully regulated signal cascades lead to the 
packaging of cytoplasm, cellular organelles and nuclear fragments into small vesicles called 
apoptotic bodies. These apoptotic bodies are phagocytosed, removing the cell with little 
disturbance to the surrounding tissue (Kerr et al, 1972). There are two processes which induce 
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apoptosis, the extrinsic and intrinsic pathways. The extrinsic pathway is initiated by 
extracellular ligands binding to surface receptors on the cell, while the intrinsic pathway is 
initiated by intracellular signals. 
DOX induces apoptosis primarily through the intrinsic pathway. DOX treatment inhibits 
protein kinase B (PKB/ Akt) signalling, resulting in the upregulation of the pro-apoptotic 
protein, Bad. The ROS generated by DOX treatment damages DNA and causes calcium ion 
(Ca2+) dysregulation. DNA damage leads to an increase in both the expression and activation 
of the tumour suppressor protein, p53. p53 then upregulates the pro-apoptotic protein, Bax, 
which localizes at the mitochondrial membrane, opening the mitochondrial apoptosis-inducing 
channel (MAC). ROS increases intracellular Ca2+ levels by releasing Ca2+ from the 
endoplasmic reticulum. This increase can generate ROS through calcium-sensitive ROS-
generating enzymes. This leads to an increase in mitochondrial Ca2+ which, once increased 
beyond threshold, causes the opening of the mitochondrial permeability transition (MPT) 
(Zhang et al, 2009). The net effect of these stimuli is the opening of mitochondrial membrane 
pores, leading to pro-apoptotic proteins leaking out of the mitochondrial intermembrane space 
and into the cytoplasm. These proteins include apoptosis inducing factor (AIF), second 
mitochondrial-redived activator of caspases (smac), cytochrome C, endonuclease G and 
omi/HtrA2. These proteins then aid in the formation of the apoptosome, activation of initiator 
caspase-9 and executioner caspase-3, which cleaves cellular components which are then 
packaged into apoptotic bodies and phagocytosed (Elmore, 2007). 
1.4. Current therapies  
1.4.1. Antioxidants 
As the pathogenesis of cardiotoxicity appears to be mediated by oxidative stress, it seems as if 
the most effective treatment would be antioxidant therapy. A meta-analysis of randomised 
controlled trials was conducted to analyse the efficacy of vitamins A, B6, B12, C, D, E and 
antioxidant therapy on cardiac disease progression. While pre-clinical trials such as in vitro 
and in vivo studies showed that vitamin and antioxidant therapies can hinder the progression 
of certain cardiac pathologies, including cardiotoxicity, clinical studies have demonstrated little 
to no protective effects (Myung et al, 2013; Sterba et al, 2013). 
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Many theories have been proposed as to why antioxidant therapies suddenly become 
ineffective in the clinical setting. The dose, duration, frequency and choice of antioxidant have 
all come into question (Steinhubl, 2008). Antioxidants may also not be effective as they may 
be unable to reach their intended target within the cell. The oxidative stress associated with 
cardiotoxicity occurs at the mitochondrial level. Many antioxidants are unable to reach the 
mitochondria and are therefore unable to scavenge the ROS damaging the cell. It may be 
necessary for antioxidants to be specifically targeted to the mitochondria in order for them to 
prove effective in the clinical setting. Another potential reason for the ineffectiveness of 
antioxidants may be that oxidative stress is only one of the factors causing cardiotoxicity. 
Therefore antioxidants are only effective against one of the many causes of the disease 
(Murphy & Smith, 2000; Adlam et al, 2017). 
1.4.2. Iron chelators 
Iron chelators have shown more promise in the clinical setting. Dexrazoxane, an iron chelator 
similar to ethylenediaminetetraacetic acid (EDTA), is used as an adjuvant therapy to limit 
cardiotoxicity. Unlike the water soluble EDTA, dexrazoxane is lipid soluble and can easily 
transverse the cell membrane and enter cells. It is then able to dissociate iron from the DOX-
Fe complexes. This elicits a cardioprotective effect, as shown by Marty et al, 2006. In this study 
women who received dexrazoxane prior to anthracycline treatment were significantly less 
(68%) likely to develop cardiac dysfunction compared to those who received anthracyclines 
alone. 
However, dexrazoxane, like all medication, has side effects. Dexrazoxane may cause pain or 
superficial phlebitis at the injection site, thus it is recommended that it is infused into a large 
vein. Alopecia, mucositis, nausea and vomiting are common in patients treated with 
dexrazoxane. These symptoms are similar to anthracycline toxicity, making it difficult to 
differentiate the cause. At near maximum doses, dexrazoxane treatment has been linked to 
increased levels of iron and zinc in urine, reversible liver dysfunction (elevated alanine 
aminotransferase/ aspartate aminotransferase) and more seriously, myelotoxicity (bone 
marrow suppression). Long term effects are also not fully understood with a potential threefold 
increase in second primary malignancies (acute myeloid leukemic/myelodysplastic syndrome). 
The findings have led to restrictions for dexrazoxane as a cardiotoxicity treatment in Europe 
(Langer, 2014). Due to the limitations of the current treatments, it is essential to find better but 
effective adjuvant therapies.  
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1.5. Autophagy 
Autophagy is a complex catabolic process which allows a cell to remove specific cytoplasmic 
components. Under specific stresses (such as starvation) certain cellular organelles and proteins 
may be regarded as surplus or defective and destroyed to ensure the survival of the cell (Yang 
et al, 2013). The macromolecules generated from autophagy are recycled allowing the cell to 
reuse the molecules again under more favourable conditions. First discovered in the early 1960s 
in rat liver, it was observed that following perfusion with glucagon, an increase in lysosomal 
activity was observed. These lysosomes contained mitochondria, safely removing the organelle 
from the cell under stressful conditions (Ashford & Porter, 1962). 
There are three distinct kinds of autophagy, namely: macro-autophagy, micro-autophagy and 
chaperone-mediated autophagy (CMA) (Kobayashi, 2015). Macro-autophagy involves the 
formation of a double membrane-bound vesicle, termed an autophagosome, delivering 
cytoplasmic components to a lysosome, fusing with the lysosome to form an autolysosome, 
which then degrades the cargo. During micro-autophagy, cytosolic components are directly 
engulfed by the lysosome through invagination of the lysosomal membrane. Both macro and 
micro-autophagy are able to engulf large cytoplasmic components through selective or non-
selective mechanisms. During CMA, targeted cytosolic components are marked with 
chaperone proteins which are recognised by the lysosomal membrane receptor lysosomal-
associated membrane protein 2A (LAMP-2A). This protein complex is translocated across the 
lysosomal membrane resulting in degradation (Glick et al, 2010). All uses of the term 
‘autophagy’ from this point onward are in reference to macro-autophagy. 
1.5.1. Mechanism  
The mechanism of autophagy is regulated by autophagy related (Atg) proteins. It follows a 
process that can be divided into a few steps; induction, autophagosome formation, 
autophagolysosomal formation and finally degradation of the cellular components (Yang et al, 
2013). Various stimuli can induce or upregulate autophagy. The unc-51 like autophagy 
activating kinase (ULK)1/ Atg1 complex has been described as the ‘mediator of nutrient 
signalling’ regulating the rate of autophagy. The activity of ULK1 is regulated by 
phosphorylation on specific sites. Adenosine monophosphate-activated protein kinase 
(AMPK), an energy sensor which responds to low levels of ATP, may phosphorylate ULK1 
(at Serine 317 and Serine 777), to promote autophagy, however the phosphorylation of ULK1 
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(at Serine 757) by mammalian target of rapamycin (mTOR), inhibits autophagy. ULK1 
phosphorylates Beclin1 (at Serine 14) to activate the class III phosphatidylinositol 3-kinase 
(PI3-K) complex, to maintain nutrient and energy homeostasis by balancing the levels of 
intracellular amino acids, carbohydrates and ATP to the level of autophagy. 
Beclin1 (Atg6) is a protein essential for the initial step of phagophore formation and autophagy 
in general. Beclin1 activity is regulated by binding proteins such as; ambral, ultraviolet 
radiation resistance associated gene protein (UVRAG) and bif-1 to induce autophagosome 
formation (Figure 1.3) while proteins such as Bcl-2 and Bcl-XL inhibit autophagy. Beclin1 is 
the point of cross talk between apoptosis and autophagy, and in response to certain apoptotic 
stimuli, caspase-3 may also cleave Beclin1. Beclin1s carboxyl-terminal then localizes at the 
mitochondria to promote apoptosis.  
Phagophore formation is the next step of autophagy. The membrane is formed from the cell’s 
phospholipid bilayer. Membrane isolation occurs at the phagophore assembly site (PAS) and 
is regulated by phosphoinositide 3-kinase (PI3-K) activity. PI3-K exists in a complex with 
Beclin1, Vps15 and Vps34 (Figure 1.3). After the initial formation, the membranes continue to 
elongate and sequester intracellular components. In this process; light chain 3 (LC3) is cleaved 
by Atg4 into LC3-I to expose its carboxyl terminal glycine. LC3-I is converted to LC3-II by 
Atg7 and Atg3 covalently attaching a phosphatidylethanolamine molecule. A covalently bound 
Atg5-Atg12-Atg16 complex sequesters LC3-II and lipids for growing the phagophore. 
Organelles which need to be removed may be targeted by ubiquitin mediated cargo recognition 
and here, E3 ubiquitin ligases are involved, where the peripheral membrane anchored proteins 
on the surface of the target organelles are tagged with polyubiquitin molecules. Cytosolic 
adaptors containing LC3 interaction domains such as p62 and neighbour of BRCA1 gene 1 
Figure 1.3: Diagram showing the induction of autophagy. 
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protein (NBR1) recognize the ubiquitin chains. The LC3 interaction domain can recruit 
autophagosomes to the target site (Figure 1.4) (Kang et al, 2011; Kobayashi, 2015). 
 
 
Once autophagosomes have successfully sequestered their cargo they fuse their membrane with 
that of the lysosome to have their contents broken down (Figure 1.5) ( Kobayashi, 2015; Yang 
et al, 2013). 
As mitochondria are a site of ATP synthesis, they are very susceptible to oxidative damage. 
Damaged mitochondria may leak pro-apoptotic proteins into the cytoplasm, inducing a 
signalling cascade leading to cell death. Damaged and dysfunctional mitochondria are removed 
through targeted autophagy in a process referred to as mitophagy. During mitophagy, targeted 
mitochondria are tagged by a ubiquitin ligase such as Parkin, Smurf1, or March5. The ubiquitin 
tagged mitochondria are recognised by p62 or histone deacetylase 6 (HDAC6) and sent to the 
autophagosome (Kobayashi, 2015). 
 
Figure 1.4: Diagram showing the formation of the autophagosome 
Figure 1.5: Diagram showing autophagolysosomal formation and degradation. 
Stellenbosch University  https://scholar.sun.ac.za
13 
 
1.5.2. Autophagic regulation 
During studies which seek to better understand the mechanisms regulating autophagy, the 
autophagic process has been activated or inhibited at various checkpoints. As autophagic 
dysregulation is complicit in many diseased states including tumour formation and survival, 
cardiovascular remodelling and heart failure, activation and inhibition may be key in the 
treatment of these diseases (Essick & Sam, 2010). Activation (Table 1.2) and inhibition (Table 
1.3) of autophagy may be achieved by numerous pharmacological agents (Yang et al, 2013). 
Name Mechanism  Target point 
AP23576 mTOR inhibitor mTOR dependent signalling 
Brefeldin A ER stressing inducer Autophagy induction  
Calpastatin  Calpain inhibitor mTOR independent signalling 
Carbamazepine IMPase inhibitor mTOR independent signalling 
CCI- 779 mTOR inhibitor mTOR dependent signalling 
Earle's balanced salt solution 
(EBSS) 
Starvation inducer Autophagy induction  
L-690,330 IMPase inhibitor mTOR independent signalling 
Lithium chloride IMPase inhibitor mTOR independent signalling 
N-Acetyl-D-sphingosine (C2- 
ceramide) 
Class I PI3K inhibitor mTOR dependent signalling 
Penitrem A Ca2+ channel blocker mTOR independent signalling 
RAD001 mTOR inhibitor mTOR dependent signalling 
Rapamycin mTOR inhibitor mTOR dependent signalling 
Small molecule enhancers 
rapamycin (SMER) 
mTOR independent 
activator 
mTOR independent signalling 
Thapsigargin ER stressing inducer Autophagy induction  
Trehalose mTOR independent 
activator 
mTOR independent signalling 
Tunicamycin ER stressing inducer Autophagy induction  
Valproic acid sodium salt IMPase inhibitor mTOR independent signalling 
Xestospongin B IP3R blocker mTOR independent signalling 
  
  
Table 1.2: List of autophagic activators, Yang et al, 2013 
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1.5.3. Autophagy during cardiac disease 
Autophagy occurs in all cells, including cardiac cells, at a basal level under normal conditions 
and is essential for the turnover of organelles. Upregulation of autophagy has been linked to 
some cardiac diseases but paradoxically has also been linked to cardioprotection, as 
upregulation of autophagy may downregulate apoptosis by removing organelles to lower 
overall nutrient and energy consumption or safely remove damaged mitochondria before they 
lead to apoptosis (Gustafsson & Gottlieb, 2008). 
During cardiac hypertrophy, autophagy appears to be detrimental. Mice which received 
transverse aortic constriction (TAC) surgery developed hypertrophy as well as an increase in 
beclin1, LC3-II and other autophagic structures. Myocardial expression of micro ribonucleic 
acid 30a (miR-30a) was decreased in TAC mouse models and rat heart myoblast (H9c2) cells 
treated with phenylephrine (PE), an miR-30a inhibitor, increased autophagy as well as the 
expression of biomarkers of cardiac hypertrophy. Autophagic inhibition however suppressed 
the cardiomyocyte hypertrophy caused by miR-30a inhibition (Weng et al, 2014). Pulmonary 
arterial hypertension (PAH), a progressive disease linked to cardiac hypertrophy, is 
characterised by an elevation in pulmonary arterial pressure and right ventricular hypertrophy. 
Rats were treated with monocrotaline to induce PAH, resulting in an upregulation of 
autophagy. Autophagic inhibition with chloroquine hindered the development of PAH (Long 
et al, 2013). While the precise mechanisms are unclear it appears that during certain cardiac 
Name Mechanism Target point 
3- Methyladenine PI 3-kinase inhibitor Autophagosome formation 
Bafilomycin A1 Vacuolar- type H ATPase 
inhibitor  
Autophagolysosome 
formation 
Cycloheximide Protein sythesis inhibitor  Autophagosome formation 
E64d Acid protease inhibitor Lysosome 
Hydoxycholoroquine Lysosomal lumen 
alkalizer 
Lysosome 
Leupeptin Acid protease inhibitor Lysosome 
LY294002 PI 3-kinase inhibitor Autophagosome formation 
Lys05 Lysosomal lumen 
alkalizer 
Lysosome 
Pepstatin A Acid protease inhibitor Lysosome 
Wortmaninn PI 3-kinase inhibitor Autophagosome formation 
Table 1.3: List of autophagic inhibitors, Yang et al, 2013 
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hypertrophic pathologies there is an increase in cardiac autophagy and inhibition of this 
autophagy reduces hypertrophy (Li et al, 2016b). 
However, during ischemia and reperfusion (I/R), autophagy may limit damage to the 
myocardium. An increase in the number of autophagosomes correlates to an increase in 
functional recovery. These autophagosomes often contain mitochondria, which otherwise 
would have leaked pro-apoptotic proteins into the cell, initiating cell death (Decker & 
Wildenthal, 1980). An upregulation of autophagy has been linked to a downregulation of 
apoptosis within the myocardium (Yan et al, 2005). Inhibition of autophagy appears to worsen 
the damage. Mice treated with rapamycin showed a decrease in infarct size whereas mice 
treated with bafilomycin A1 (BAF- A1), a membrane-permeant lysosomal inhibitor, which 
inhibits autophagosome-lysosome fusion thus inhibiting the final step of autophagy 
(degradation), showed an increase in infarct size (Kanamori et al, 2011). 
Based on the above studies, it is clear that autophagy is a double-edged sword that can be 
detrimental or beneficial depending on the context in which it is studied. 
1.5.4. Autophagy in the context of DOX 
There have been numerous studies conducted to evaluate the relationship between DOX 
treatment and autophagy. Many of these studies have concluded that DOX treatment does 
affect autophagy. There is however much debate about whether autophagy is upregulated or 
downregulated in this context. Numerous studies provide evidence for the upregulation of 
autophagy (Table 4). Rather counterintuitively there are also numerous studies providing 
evidence for downregulation of autophagy (Table 5). It is worth noting that, although not 
explicitly stated, majority of these studies appear to be conducted in an acute setting. 
The reason for this paradox may be due to many factors. There are many inconsistencies across 
the studies which may explain the inconsistent results. The choice of model appears to affect 
the result. Where in vivo or in vitro studies conducted in rats point to autophagic upregulation, 
studies conducted in mice point to downregulation. Different studies use different modulators 
of autophagy. These modulators may have off target effects aside from regulating autophagy 
which may skew assay results. 3-methyladenine (3-MA) is used to inhibit autophagy in many 
studies. It has no effect, however, on beclin1-independent forms of autophagy and may 
upregulate autophagy under certain circumstances. The assays used also differ from study to 
study as well as the biomarker assessed. Many studies favoured western blots, with the focus 
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being on LC3 proteins. Many of the earlier studies did not blot for both LC3 and p62 proteins, 
rather just LC3. Increased LC3 may indicate upregulated of autophagosome formation as this 
biomarker is present during the early stages of autophagy but this may be incomplete. Studies 
which blotted for LC3 and p62 showed an increase in both proteins, thus indicating upregulated 
autophagosome formation but impaired clearance. This means that while autophagy is induced, 
the cargo is not removed and may lead to detrimental consequences within the cell autophagy 
(Dirks-naylor, 2013; Klionsky et al, 2016; Bartlett et al, 2017). 
   
Table 1.4: List of studies suggesting DOX upregulates autophagy 
Author, 
Year 
Model 
 
DOX dose Assay Treatment 
Lu et al, 
2009 
In vivo: Male Sprague-
Dawley rats 
In vitro: Sprague- Dawley 
NRCM 
In vivo: 6x 2.5 mg/kg IP 
injection (CD: 15 mg/kg) 
In vitro: 1 mg/L -24hrs 
WB: Beclin1 
FM, FC: 
Autophagic 
vacuoles 
3-MA 
Kobayashi et 
al, 2010 
In vitro: Sprague- Dawley 
NRCM 
 
 
In vitro: 1 µM -18 hrs WB: LC3-II, p62 
FM: LC3 
3-MA, Rapa, 
Baf-A1 
Chen et al, 
2011 
In vitro: Sprague- Dawley 
NRCM 
In vitro: 1 µM -16 hrs WB: LC3-II 
FM: LC3 
3-MA, Rapa, 
Baf-A1 
Dimitrakis et 
al, 2012 
In vitro: Wistar NRCM In vitro: 1 µM, 10 µM, 
20 µM, 50 µM -48hrs 
WB: LC3-II 
FM: LC3 
Lactacystin, 
Chloroquine 
Xu et al, 
2012 
In vitro: Sprague- Dawley 
NRCM 
In vitro: 1µM -18hrs WB: Beclin1, Atg5, 
Atg12, LC3-II, p62 
FM: LC3 
3-MA, Baf-
A1, 
Resveratrol 
Smuder et 
al, 2013 
In vivo: Male Sprague-
Dawley rats 
 
In vivo: 1x 20 mg/kg IP 
injection (CD: 20 mg/kg) 
WB:  Beclin1, 
Atg5, Atg12, Atg7, 
Atg4, LC3, 
Cathepsin 
Exercise  
Sun et al, 
2014 
In vivo: C57BL/6J, 
ALDH2 KO/ ALDH2 
overexpression mouse 
In vivo: NYHA III-IV 
human tissue 
In vitro: NMCM, AMCM 
In vivo: 6x 15 mg/kg IP 
injection (CD: 90 mg/kg) 
In vitro:1µM -4hrs adult/ 
1 µM -18hrs neonatal 
WB: Beclin1, Atg5, 
LC3-II 
3-MA, Rapa 
Wang et al, 
2014 
In vivo: C57BL/6J mouse 
In vitro: H9C2 cells 
In vivo: 8 mg/kg IP 
injections (CD: 8 mg/kg) 
In vitro: 10 µM/L -
12/24hrs 
WB: LC3-II, 
AMPK, mTOR 
FM: LC3 
3-MA, cpd 
C, ghrelin 
Cao et al, 
2016 
In vivo: C57BL/6J mouse 
In vitro: NRCM, H9C2 
cells 
In vivo: 2x 10 mg/kg IP 
injections  
(CD: 20 mg/kg) 
In vitro: 0.1-5 µM -24hrs 
WB: Beclin1, p62, 
LC3-I, LC3-II 
FM: LC3 
Rapa, APS 
NRCM: Neonatal Rat Cardiomyocytes. NMCM: Neonatal Mouse Cardiomyocytes.  
ARCM: Adult Rat Cardiomyocytes. AMCM: Adult Mouse Cardiomyocytes. 
IP: Intraperitoneal. CD: Cumulative Dose. WB: Western Blot. FM: Florescence Microscopy. FC: Flow 
Cytometry.  
3-MA: 3-methyladenine. Rapa: Rapamycin. Baf-A1: Bafilomycin-A1.  
Cpd C: AMPK inhibitor compound C. APS: Astragalus polysaccharide. 
 
Stellenbosch University  https://scholar.sun.ac.za
17 
 
 
 
  
Author, 
Year 
Model 
 
DOX dose Assay Treatment 
Kawaguchi 
et al, 2012 
In vivo: GFP-LC3 mouse 
In vitro: GFP-LC3 
NMCM 
In vivo: 2x 10 mg/kg IP 
injections (CD: 10 mg/kg) 
In vitro: 0.1 µM/L -6hrs 
WB: LC3-II, p62 
FM: LC3 
Chloroquine, 
Starvation 
Hoshino et 
al, 2013 
In vivo: C57BL/6J, p53/ 
Parkin/ p21 deficient. 
GFP- LC3 mouse 
In vitro:  HL-1 
cardiomyocytes, MEFs 
In vivo: 5x 2.5mg/kg IP 
injection (CD: 12.5mg) 
In vitro: 0.02 µM -24hrs 
IHC: LC3 
EM: autophagic 
vacuoles  
3-MA, Baf-
A1 
Sishi et al, 
2013 
In vivo: GFP-LC3 mouse 
In vitro: H9C2 cells 
In vivo: 2x 10 mg/kg IP 
injections (CD: 20 mg/kg) 
In vitro: 3 µM -24hrs 
WB: LC3-II, p62 
 
Baf-A1, 
Rapa 
Li et al, 
2014 (b) 
In vivo: C57BL/6J, Nrf2−/
− mouse 
In vitro: Wistar NRCM 
In vivo:1x 25 mg/kg IP 
injection (CD: 25 mg/kg) 
In vitro: 1 µM -24hrs 
WB:  LC3-II, p62, 
Atg5, Atg7, 
Cathepsin 
Chloroquine 
Katamura et 
al, 2014 
In vivo: C57BL/6J, GFP- 
LC3 mouse 
In vitro: Wistar NRCM 
In vivo:1x 20 mg/kg IP 
injection (CD: 20mg/kg) 
In vitro: 1 µM -2hrs 
WB: LC3-II 
FM: Autophagic 
vacuoles 
3-MA, 
Curcumin 
Bartlett et al, 
2016 
In vivo: Sprague-Dawley 
rats 
In vitro: NRCM, ARCM, 
AMCM, H9C2 
In vivo: 5x 10 mg/kg IP 
injections (CD:50 mg/kg) 
In vitro:2 µM -
2/6/12/24hrs 
WB: ULK1, 
Beclin1, p62, LC3-
I, LC3-II 
Chloroquine 
Lai et al, 
2016 
In vivo: Sprague-Dawley 
rats 
In vitro: ARCM, H9C2 
In vivo: 6x 2.5 mg/kg IP 
injections (CD: 15 mg/kg) 
In vitro: 2 µM 
WB: Beclin21, 
LC3-I, LC3-II 
 
Li et al, 
2016 (a) 
In vivo: Beclin1 +/- mouse 
In vitro: NRCM, H9C2 
In vivo: 4x 5 mg/kg 
injections (CD: 20 mg/kg) 
In vitro: 1 µM -24hrs 
WB: LC3-1, LC3-
II, p62  
Baf-A1 
Park et al, 
2016 
In vitro: human cardiac 
progenitor cells  
In vitro: 0.01-5 µM -24hrs WB: Beclin1, 
LC3-1, LC3-II, 
p62 
FM: LC3 
Rapa 
Pizarro et al, 
2016 
In vitro: NRCM In vitro: 1 µM -24hrs WB: Beclin1, 
LC3-1, LC3-II, 
p62 
3-MA, Rapa, 
Baf-A1 
NRCM: Neonatal Rat Cardiomyocytes. NMCM: Neonatal Mouse Cardiomyocytes.  
ARCM: Adult Rat Cardiomyocytes. AMCM: Adult Mouse Cardiomyocytes. 
IP: Intraperitoneal. CD: Cumulative Dose. WB: Western Blot. FM: Florescence Microscopy. FC: Flow 
Cytometry.  
3-MA: 3-methyladenine. Rapa: Rapamycin. Baf-A1: Bafilomycin-A1.  
Cpd C: AMPK inhibitor compound C. APS: Astragalus polysaccharide. 
 
 
 
 
Table 1.5: List of studies suggesting DOX downregulates autophagy 
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1.6. Starvation 
Starvation is a complex process which affects every system in the body. The literature on 
starvations effects on these systems is extensive. For the sake of relevance and concision, 
starvations interactions with autophagy and chemotherapy will only be discussed.  
1.6.1. Starvation and autophagy 
Starvation is one of the most basic natural inducers of autophagy. During nutrient deprivation, 
many cell types upregulate autophagy. This may be because organelles no longer receive the 
nutrients they require to function effectively, or organelles are surplus to cell survival as energy 
becomes scarce. Biochemically, starvation induces autophagy through AMPK activation of the 
ULK1/ Atg1 complex (Takeshige et al, 1992; Roach, 2011). Cardiomyocytes, like many cell 
types, upregulate autophagy as a result of starvation. Research conducted by Kanamori et al 
(2009) where mice were starved for 12, 24, 48 and 72 hours, demonstrated a direct correlation 
between starvation time and autophagic activity. The longer starvation time the greater 
autophagic activity. It was also observed that under these conditions, ATP levels significantly 
decreased in the myocardium and autophagy appeared to attenuate this to some extent, as 
inhibition of autophagy during starvation reduced ATP levels significantly more than 
starvation alone (when autophagy was allowed to occur). It was concluded that the insufficient 
ATP supply contributed to the cardiac dysfunction observed in the mice which had autophagy 
inhibited during starvation. Thus, starvation induced autophagy elicits a cardioprotective effect 
within this context. 
1.6.2. Starvation and chemotherapy  
Starvation also elicits protective effects against oxidative stress and chemotherapeutic damage. 
It was found that in yeasts, worms and mice which were starved prior to oxidative stress 
induction or etoposide (chemotherapeutic) treatment, the mortality rate was significantly 
reduced. Although it is unclear why starvation had this protective effect, it is thought that the 
decrease in IGF1 (caused by starvation) is responsible (Raffaghello et al, 2008). While the 
exact mechanisms remain to be elucidated, there is evidence to suggest that starvation elicits 
protective effects through multiple pathways, both dependent and independent of autophagy. 
More appropriately to this study, starvation prior to DOX treatment elicited a cardioprotective 
effect. In a study conducted by Kawaguchi et al (2012) rats were starved for 48 hrs prior to 
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DOX treatment. In this study DOX treatment downregulated autophagy, prior starvation 
however attenuated this downregulation. DOX treatment also depleted myocardial ATP, again 
autophagy attenuated this. Starvation also improved cardiac function as well as significantly 
reducing atrophy and fibrosis. This study however was conducted on acute cardiotoxicity. 
1.7. Rapamycin 
Rapamycin is an mTOR inhibiting drug used to upregulate autophagy. First isolated in the early 
1970s from Streptomyces hygroscopicus bacteria found in soil on the Easter Islands. It was 
named rapamycin after the islands native name, Rapa Nui. Originally, rapamycin was shown 
to have antifungal properties but later shown to have other uses (Vezina et al, 1975).  
1.7.1. Modes of action 
It has since been identified that rapamycin has anti-proliferative and immunosuppressive 
properties in mammalian cells, thus leading to the investigation of the modes of action of this 
compound. Rapamycin has previously been shown to be a potent inhibitor of S6K1 activation, 
a serine/threonine kinase activated by a variety of agonists and an important mediator of PI3-
K signalling. Rapamycin forms a functional complex by binding with a 2 kDa FK506-binding 
protein (FKBP12). This complex binds to and inhibits mTOR complex 1 (mTORC1), a 
pathway associated with autophagic regulation. Biochemical and genetic analysis of mTOR 
has shown that two distinct complexes are present; mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). Acute rapamycin exposure only effects (inhibits) mTORC1, however 
chronic exposure has been shown to inhibit mTORC2 in some cell types (Laplante & Sabatini, 
2013). Figure 1.6 shows how rapamycin activates autophagy, compared with starvation. 
Multiple signals activate mTORC1, including growth factors, nutrients, energy, and oxygen 
status. Depending on the signal, responses include processes for cell growth and proliferation, 
micro ribonucleic acid (mRNA) biogenesis, protein, lipid, nucleotide and protein synthesis, 
energy metabolism, and autophagy. Dysregulation of mTORC1 and the associated pathways 
are common in cancers. In contrast to mTORC1, far less is known about mTORC2. It has been 
found that mTORC2 activation of Akt and serum and glucocorticoid-regulated kinase 1 
(SGK1) can mediate cell survival (Li et al, 2014a). 
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1.7.2. Rapamycin and cancers 
There are many cancers which display an increase in mTORC1 activation. This is due to either 
the mutations in oncogenes (Akt, PI3-K, Ras) or tumour suppressors liver kinase B1 (LKB1), 
phosphatase and tensin homolog (PTEN), tuberous sclerosis proteins 1/2 (TSC1/2) which are 
upstream regulators of mTORC1. To meet the demands of unregulated proliferation, cancerous 
cells often possess alterations to energy metabolism and nutrient uptake processes. These 
processes are directly influenced by the mTORC1 pathways. Oncogenic mTORC1 activation 
promotes gene expression which is involved in cancer cell metabolic reprogramming. This 
promotes lipid and protein synthesis, glutamine metabolism and glycolysis (Li et al, 2014a).  
Due to poor solubility and pharmacokinetics several rapamycin analogs, collectively known as 
rapalogs, have been developed. Temsirolimus and everolimus, two water-soluble rapalogs, 
were approved by the Food and Drug Administration (FDA) in 2007 and 2009 respectively, as 
a treatment for advanced renal cancer carcinoma (RCC). Temsirolimus has been tested in 
several clinical trials as treatment for advanced or recurrent endometrial cancer, and relapsed 
or refractory mantle cell lymphoma (MCL) and advanced neuroendocrine carcinoma (NEC) 
(Benjamin et al, 2011). Everolimus was approved by the FDA as a treatment for progressive 
neuroendocrine tumours (PNET) of pancreatic origin. Trials are also being conducted to 
evaluate the effect of everolimus as a treatment for advanced gastric cancer, advanced 
hepatocellular carcinoma and advanced non-small cell lung cancer (NSCLC). Rapalogs have 
had only modest effects on solid tumours in the clinical setting. The reasons for the modest 
effects have not been fully established but is likely related to the numerous mTORC1 regulated 
negative feedback loops supressing upstream signalling, such as PI3-K Akt signalling, receptor 
tyrosine kinases (RTKs) and Ras-ERK pathways which rapamycin may reactivate. Strategies 
to overcome these limitations are currently in development ( Li et al, 2014a). 
  
Figure 1.6: Simplified diagram showing starvation vs rapamycin autophagic induction. 
Stellenbosch University  https://scholar.sun.ac.za
21 
 
1.7.3. Rapamycin and cardioprotection 
Rapamycin treatment has a preconditioning-like effect during I/R injury. Mice pre-treated with 
rapamycin have a significant reduction in infarct size. In vitro analysis on cardiomyocytes 
showed rapamycin reduced apoptosis and necrosis during I/R injury. Cardioprotection may be 
due to inhibition of protein synthesis and regulation of mitochondrial potassium ATP 
(mitoKATP) channels. Opening of mitoKATP channels is one method of cardioprotection. It 
has led to speculation that opening of mitoKATP channels by rapamycin leads to its 
cardioprotective effect during I/R. The precise mechanism of mitoKATP opening is unclear, 
there are however some theories. Rapamycin-induced mTOR inhibition upregulates PI3-K and 
Akt kinases. These kinases are key mediators in the activation of mitoKATP channels. Co-
localization of mTOR at the mitochondria allows for the regulation of mitochondrial membrane 
channel activity (Khan et al, 2006). This suggests that rapamycin may be a potentially effective 
therapy due to its ability to upregulate autophagy, as well as having antineoplastic and 
cardioprotective effects. 
In summation, DOX is an effective and indispensable chemotherapeutic. Cardiotoxicity 
however is a deadly problem which limits DOX usage. While the mechanisms behind DOX- 
induced cardiotoxicity are poorly understood it believed to be as a result of increased ROS. 
Despite this, potential adjuvant therapies like antioxidants and iron chelators which target ROS 
production, appear to be ineffective or unviable. Despite the contentious literature, it is believed 
that DOX downregulates autophagy. While the role of autophagy is cardiac disease is poorly 
understood it has the potential to be an effective adjuvant therapy. Upregulation of autophagy, 
through pharmacological (rapamycin) or physiological (starvation) inducers, may attenuate the 
damage by removing damaged cellular components before they can generate deadly signal 
cascades as well as generate macromolecules to facilitate healing. 
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1.8. Problem statement 
DOX is a potent, effective chemotherapeutic agent that has resulted in an increase in the 
number of cancer survivors. However due to its severe side effects, especially chronic 
cardiotoxicity its clinical use is limited. Limited use may have a lesser antineoplastic effect and 
still may result in cardiotoxicity. This is detrimental to both cancer patients and cancer 
survivors. 
1.9. Hypothesis 
DOX treatment reduces autophagic activity which contributes to the detrimental effects 
observed in the myocardium. Therefore, by upregulating autophagy prior to DOX 
administration, it is assumed that the negative effects will be attenuated. 
1.10. Aims and objectives 
1.10.1. Aims 
• To induce an in vivo mouse model of prolonged DOX treatment 
• Establish DOXs effect on autophagy within this model 
• Attenuate cardiotoxicity with rapamycin and starvation 
1.10.2. Objectives 
• Identify cardiac damage caused by DOX treatment 
• Asses levels of autophagic proteins 
• Asses the role of oxidative stress and apoptosis in the pathogenesis of cardiotoxicity 
• Establish the effects of rapamycin and starvation on DOX induced cardiac damage 
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Chapter 2: Methodology  
2.1. Ethical Considerations and Animal Care 
This animal study was reviewed and approved by the Stellenbosch University Animal Ethics 
committee (reference number: SU-ACUM13-00013). Three-week-old male black 6 mice 
(C57BL/6) were housed in the animal house at the University of Stellenbosch on a 12-hour 
day- night cycle and allowed access to food and water ad libitum. After one week of 
acclimatisation, mice were randomly divided into six different treatment groups (Figure 2.1); 
vehicle (control), DOX, rapamycin, starvation, DOX and rapamycin and DOX and starvation. 
After an additional week of acclimatisation, the treatment protocol commenced. 
2.2. Treatment Protocol 
The DOX treated group received 2 mg/kg DOX weekly, administered via intraperitoneal 
injection. This treatment continued for a total of eight weeks, resulting in a cumulative dose of 
16 mg/kg. This dosage was found in literature and appears to be amongst the lower dosage 
range which induces cardiotoxicity, thus mimicking the low dosages given to humans in an 
attempt to avoid cardiotoxicity. This treatment regimen involves a low dose over an extended 
period of time rather than a single bolus injection, which results in the gradual development of 
cardiotoxicity, while reducing other potential acute side effects typically associated with bolus 
treatment (Bernstein et al, 2012; Ghigo et al, 2015; Berthiaume et al, 2005; Zhou et al, 2001). 
This treatment regimen also allows multiple pre-treatments, thereby increasing potential 
cardioprotective effects. The control group (vehicle) received a saline injection of equivocal 
volume to the DOX treated group. The rapamycin group received 2 mg/kg rapamycin weekly. 
Figure 2.1: Flow Diagram of treatment groups in this study.  
Male Black 6 
(C57BL/6) 
Control   Rapamycin  Starvation  Doxorubicin  Dox + Rapa  Dox + Starve  
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This dosage is based on previous research which used rapamycin to induce a cardioprotective 
effect prior to I/R (Khan et al, 2006; Yang et al, 2010; Hernández et al, 2011). The DOX and 
rapamycin group received rapamycin 30 minutes prior to receiving DOX. 
The starvation group was starved from food for 24 hours each week but were allowed free 
access to drinking water (Kanamori et al, 2009). The DOX and starvation group were starved 
for 24 hours prior to receiving DOX. These treatment regimens were carried out weekly for a 
period of eight weeks, and all injections were performed via intraperitoneal injection. Animals 
were weighed weekly and their welfare was monitored daily. All animals survived the 
treatment protocol. 
2.2.1. Sample collection 
One week after the final treatment, mice were euthanised via cervical dislocation. The whole 
heart was harvested, weighed and sectioned coronally into halves. One half was snap frozen in 
liquid nitrogen for biochemical analysis and stored at -80 °C. The other half was preserved in 
a 4% buffered formaldehyde (approximately 10% formalin) solution (Merck, 1004965000) for 
histological analysis. 
Figure 2.2: Timeline of treatment protocol 
Figure 2.3: Flow Diagram of cardiac samples collected. 
Western blot: 
LC3 
Caspase 3 
Fluorometry: 
GSH/GSSG 
CDs 
Histology: 
H&E 
Picrosirius red  
Liquid nitrogen 
(-80°C) 
4% Buffered 
formaldehyde  
End 
Point  
Treatment 
End 
Treatment 
Start Born  
1 4 2 5 6 3 8 9 7 10 11 13 12 14 0 
Received  
Weeks  
Treatment 
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2.3. Histological Analysis 
2.3.1. Tissue processing 
The tissue preserved in buffered formaldehyde solution was processed and embedded in 
paraffin wax using a Leica EG1150 H tissue processor. After processing, the tissue was 
sectioned into 5 µm sections using a Leica RM 2125 RT microtome. Cardiac sections were 
placed in a warm water bath (±40 ºC) then placed onto a glass microscope slide and in a 65 ºC 
oven for roughly five minutes to adhere (full protocol available in Appendix B, page 59). 
2.3.2. Haematoxylin & Eosin (H&E) stain 
H&E staining was performed in order to assess the general morphology of the tissue and to 
measure the cross-sectional area of the cardiomyocytes. The cationic haematoxylin stains the 
negatively charged substances within the tissue (such as DNA) blue and the anionic eosin stains 
the positively charged substances within the tissue (such as proteins) pink. This stain was 
performed using a Leica ST5010 Autostainer XL automated staining machine (full protocol 
available in Appendix B, page 60). 
2.3.3. Picrosirius red stain 
The Picrosirius red stain was performed in order to assess the amount of fibrosis within the 
tissue. The hydrophilic Sirius red binding to acid groups on the collagen fibres while the 
hydrophobic picric acid staining the rest of the tissue yellow. This stain was performed by hand 
(full protocol available in Appendix B, page 60). 
2.3.4. Image analysis 
The stains were imaged using a Nikon Eclipse E4000 microscope and NIS Elements imaging 
software (version 4.10) and analysed using ImageJ software (version 1.49). The H&E images 
were captured at 40x magnification and stitched together to create an image of the entire organ 
section. These images were used to assess any major structural abnormalities. In a modification 
of the imaging protocol used by Gilliam et al (2009), 6 random H&E images were taken per 
treatment group, at 200x magnification and 10 fibres were measured per image. 
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In modification of the imaging protocol used by Kanamori et al (2011), 15 random picrosirius 
red images were taken per group, at 400x magnification. Fibrosis was displayed as a percentage 
of the total tissue area. 
2.4. Biochemical analysis 
2.4.1. Oxidative Stress analysis 
Fluorometry was conducted to assess oxidative stress levels. Glutathione (GSH), glutathione 
disulfide (GSSG) and conjugated dienes (CDs) levels were assessed. GSH levels were 
compared to GSSG, the oxidized form of GSH, as a ratio. This provided an assessment of ROS 
and as GSSG is reduced back to GSH, an assessment of antioxidant status as well. CDs act as 
a marker of early lipid peroxidation and thus are indicative of oxidative damage in general 
(John Betteridge, 2000; Zitka et al, 2012). 
For the GSH assay tissue was homogenised in phosphate buffer and for the GSSG assay tissue 
was homogenised in a 1% 1-Methyl-2-vinylpyridinium triflate phosphate (M2VP) buffer 
solution. The homogenates were centrifuged at 12 000 rpm, the pellet was discarded, and the 
supernatant was used. Absorbance was measured at 412 nm every 30 seconds for three minutes 
using a Fluoroskan Ascent Microplate Fluorometer (Thermo Fisher Scientific), GraphPad 
Prism (version 6.01) was used to generate a standard curve. The concentrations of total GSH 
and GSSG were then calculated using the standard curve of GSH (full protocol available in 
Appendix B, page 63).  
To perform the CDs assay, excess lysate from the GSH group was modified. A 1:2 ratio of 
chloroform: methanol was added to the lysates. The lysates were centrifuged at 14 000 rpm. 
The bottom layer in the heterogeneous solution was removed and refrigerated overnight to 
allow evaporation. The next day, cyclohexane was added, and the lysates were analysed by 
measuring the absorbance at 380 nm. Concentration was calculated by dividing the absorbance 
by the excitation coefficient (full protocol available in Appendix B, page 64). 
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2.4.2. Western blot analysis 
Western blots were performed to assess apoptotic and autophagic levels through the protein 
expression of caspase 3 (apoptotic marker) and LC3 (autophagic marker), respectively. Tissue 
lysates were prepared by homogenizing tissue in radioimmunoprecipitation assay (RIPA) 
buffer. The homogenates were centrifuged at 15 000 rpm, the pellet was discarded, and the 
supernatant was centrifuged again. A Direct Detect Spectrometer was used to calculate the total 
protein concentration. This method of protein quantification involves pipetting a small amount 
of the protein lysate onto a hydrophilic polytetrafluoroethylene (PTFE) membrane. Mid- 
Infrared (MIR) light is then used on the membrane, allowing for amide detection and 
subsequent protein quantification. Protein samples were prepared in Laemmli’s buffer and 20 
µg of protein was loaded in each well. Proteins were separated on a 12% acrylamide gel run at 
100V for approximately three hours. The proteins were transferred to a low-fluorescence 
polyvinylidene fluoride (LF PVDF) membrane using a Trans-Blot Turbo Transfer System 
ready-to-assemble (RTA) Transfer kit (Bio-Rad, 170 - 4274). The membranes were blocked in 
5% milk for two hours then incubated in primary antibody solution (1:1000) for approximately 
72 hours at 4 °C under constant agitation. The membranes were then washed in tris buffered 
saline with tween 20 (TBS-T) and incubated in the appropriate secondary antibody (1:1000) 
for one hour at room temperature under constant agitation. Enhanced chemiluminescent (ECL) 
detection was used to image membranes, clarity ECL substrate (Bio-Rad, 170 - 5061) was 
added and membranes were imaged on a ChemiDoc XRS+ system (Bio-Rad, 170 - 8265) (full 
protocol available in Appendix B, page 66). 
Table 2.1: List of Antibodies used.  
Primary antibodies 
Name  Size (kDa)  Company Catalogue no 
Caspase 3 35 Cell Signalling 9665 
LC-3 16,14 Cell Signalling 2775 
Secondary antibody 
Name  Company Catalogue no  
Anti- mouse IgG, HRP-linked Antibody Cell Signalling 7076 
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2.5. Statistical analysis  
Due to sample size a Kolmogorov- Smirnov (KS) normality test was done to test for a normal 
distribution of data. If distribution was normal, an analysis of variance (ANOVA) was 
conducted to test for significant differences across the groups. A Fisher’s Least Significant 
Difference (LSD) post hoc test was applied, where appropriate, as it mimics the t-test. If 
distribution was non-normal, a Kruskal-Wallis test was conducted to test for significant 
differences across groups. A t-test was done to compare specific groups if the groups were both 
normally distributed, if however, one (or both) were non-normally distributed a Mann-Whitney 
U test was done. All values are presented as mean ± standard error of mean (SEM). Statistical 
analyses were conducted in GraphPad Prism (version 6.01). P-values were considered 
significant when P < 0.05. 
 
 
  
Figure 2.4: Flow Diagram of statistical tests used 
Kolmogorov- Smirnov 
Normality test 
ANOVA 
Mann- Whitney U/ 
T- test 
Kruskal- Wallis  
Fisher’s Least 
Significant Difference 
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Chapter 3: Results  
3.1. Physical assessment 
3.1.1. Animal mass 
As DOX treatment is known to induce weight loss, the experimental animals in this study were 
weighed weekly to determine the effect of DOX on animal mass. Furthermore, as some of the 
animals were starved in order to induced autophagic activity, either in the presence or absence 
of DOX, it was important to monitor these animals for any changes in weight. Animals were 
initially weighed at week one, prior to any treatment. Treatment began at week two and ended 
at week nine. Animals were then euthanised at week 10. Significant differences were observed 
between the control and all the DOX groups (Figure 3.1). These differences were first observed 
in week five and continued until the end of the study. 
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Figure 3.1: Line graph displaying animal mass in grams over time in weeks. Red line indicating 
treatment duration. DOX vs Control (*), DOX+ Rapa vs Control (#) and DOX+ starve vs Control ($). Single 
symbol (p<0.05), Double symbol (p<0.01). All data displayed in g as mean ± SEM. n=6-7. Abbreviation: 
C (control), R (rapamycin), S (starvation), D (DOX), D+R (DOX+ Rapa), D+S (DOX+ Starve) 
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3.1.2. Cardiac mass 
To determine the effect of DOX and the adjuvant therapies on myocardial mass, the wet weight 
of the organ was taken following euthanasia. The mass of the heart was then compared to the 
mass of animal. This was done to assess potential hypertrophy or atrophy of cardiac muscle. 
No significant differences were present (Table 3.1). 
3.2.  Histological analysis 
3.2.1. Overall qualitative assessment 
As previously mentioned, DOX treatment causes cardiac damage. Whole heart images showed 
microscopic damage, to some degree, across all groups. However due to poor image quality it 
is not possible to infer whether the damage seen in the groups occurred as a result of the 
treatment protocol or post mortem during the tissue processing and staining procedures (Figure 
3.3). 
  
Table 3.1: Cardiac mass in mg and cardiac mass as a ratio to animal body weight, displayed in arbitrary 
units. All data displayed as mean± SEM. n=6-7. 
 Control Rapamycin Starvation DOX DOX + 
Rapa 
DOX + 
Starve 
Cardiac 
mass 
(mg) 
184.50± 
25.28 
168.30± 
19.91 
127.50± 
17.93 
160.90± 
14.43 
143.70± 
12.31 
144.70± 
14.56 
Cardiac: 
Animal 
mass 
(AU) 
6.013± 
0.699 
5.937± 
0.470 
5.077± 
0.350 
6.410± 
0.462 
5.804± 
0.470 
5.864± 
0.439 
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3.2.2. Cardiomyocyte area 
DOX treatment is known to cause cardiomyocyte death and negatively affect cardiac function. 
Measurement of cardiomyocyte cross-sectional area or ‘thickness’ is a good assessment of 
cardiac health, as these cells are responsible for the contractions of the heart. Therefore, a loss 
of cardiomyocytes or a decrease in cardiomyocyte area may correlate to a decrease in cardiac 
function. A significant decrease in cardiomyocyte area was observed in the DOX group (97.41± 
4.1, p<0.01) compared to the control group (112.6± 4.32). There are significant differences 
between other groups, but none relevant to this study.  
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Figure 3.2: Average Area of Cardiac Cardiomyocytes in um2. Values expressed as mean ± SEM 
(**p<0.01), (n=6) Abbreviation: C (control), R (rapamycin), S (starvation), D (DOX), D+R (DOX+ Rapa), 
D+S (DOX+ Starve) 
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Figure 3.3: Haematoxylin and Eosin stained cardiac tissue. Whole images expanded to 400x 
magnification. Scale bar = 50µm. Abbreviation: C (control), R (rapamycin), S (starvation), D (DOX), D+R 
(DOX+ Rapa), D+S (DOX+ Starve) 
C 
R 
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D 
D+ R 
D+ S 
Stellenbosch University  https://scholar.sun.ac.za
33 
 
 
3.2.3. Fibrosis  
The extracellular matrix (ECM) of the heart is comprised of fibrous connective tissue. During 
certain stresses fibroblast proliferation is upregulated and thus many cardiac pathologies, 
including DOX exposure, result in excessive fibrous tissue in the ECM. Measuring the amount 
of fibrous tissue in the heart is a good indicator of cardiac health as excessive fibrosis may 
decrease cardiac function. A significant increase in fibrosis was observed in the DOX group 
(2.07± 0.22, p<0.001) compared to the control group (1.05± 0.18). There was also a significant 
decrease in fibrosis in the DOX+ starve group (1.21± 0.18, p<0.01) compared to the DOX 
group (2.07± 0.22) (Figure 3.5). There are significant differences between other groups, but 
none relevant to this study. 
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ФФ 
Figure 3.4: Average Percentage of Cardiac fibrosis. Values expressed as mean ± SEM (***p<0.001), 
(ФФp<0.01), (n=3) Abbreviation: C (control), R (rapamycin), S (starvation), D (DOX), D+R (DOX+ Rapa), 
D+S (DOX+ Starve) 
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Figure 3.5: Picrosirius red stained cardiac tissue. Whole images expanded to 400x magnification. Red 
indicating fibrious tissue. Yellow indicating non- fibrious tissue. Scale bar = 50µm. Abbreviation: C 
(control), R (rapamycin), S (starvation), D (DOX), D+R (DOX+ Rapa), D+S (DOX+ Starve) 
C 
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D 
D+ R 
D+ S 
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3.3. Oxidative Stress Markers 
It is often proposed that the most likely mechanism of action for DOX-induced cardiotoxicity 
is oxidative stress. Because of this the effects of DOX, and the adjuvant therapies, on oxidative 
stress levels were measured. 
3.3.1. Antioxidant Status 
When GSH neutralizes free radicals it donates an electron, oxidizing to GSSG. Therefore, a 
decrease in GSH coupled with an increase in GSSG is indicative of a state of oxidative stress. 
Both GSH and GSSG were measured and a ratio of GSH: GSSG was used as a marker of 
oxidative stress. The GSH: GSSG ratio was analysed. No significant differences were present. 
 Table 3.2: GSH and GSSG in µMol/g and GSH: GSSG ratio in arbitrary units as mean± SEM. n=3-6. 
 
3.3.2. Lipid peroxidation 
Unsaturated fatty acids found in cell (and other organelle) membranes are a common target for 
free radicals. This oxidation results in a CDs. CDs are an early marker of lipid peroxidation as 
they may undergo further oxidation to form other products. No significant differences were 
present. 
Table 3.3: CDs expressed in µMol/g as mean± SEM. n=4-6.  
 Control Rapamycin Starvation DOX DOX + 
Rapa 
DOX + 
Starve 
GSH 
(µMol/g) 
0.4429± 
0.0548 
0.4004± 
0.0631 
0.3725± 
0.0857 
0.4447± 
0.0126 
0.4023± 
0.0479 
0.4221± 
0.0607 
GSSG 
(µMol/g) 
0.0344± 
0.0051 
0.0380± 
0.0032 
0.0415± 
0.0017 
0.0413± 
0.0014 
0.0373± 
0.0013 
0.0397± 
0.0015 
GSH: GSSG 
(AU) 
0.0879± 
0.0228 
0.1202± 
0.0417 
0.1278± 
0.0356 
0.0932± 
0.0040 
0.0966± 
0.0107 
0.1040± 
0.0178 
 Control Rapamycin Starvation DOX DOX + 
Rapa 
DOX + 
Starve 
CDs 
(µMol/g) 
0.0585± 
0.0064 
0.0498± 
0.0036 
0.0567± 
0.0056 
0.0883± 
0.0247 
0.0694± 
0.0093 
0.0787± 
0.0048 
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3.4. Western blot 
3.4.1. Apoptosis 
Caspase 3 is an executioner caspase, it is responsible for cleaving various proteins within the 
cell causing DNA damage and eventually successful apoptosis. Caspase 3 exists in 2 forms, 
the inactive procaspase (35 kDa) and the cleaved active caspase (17/19 kDa). Protein levels 
were measured against stain-free total protein instead of β-actin or glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), as it is believed to produce more accurate results (Gilda & Gomes 
2013). The whole inactive protein was detected but the cleaved active protein was not. No 
significant differences were present. 
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Figure 3.6: Caspase 3 protein expression. Values expressed as a percentage of control as mean ± SEM. 
n=4-6. Representative western blot bands for each group. Abbreviation: C (control), R (rapamycin), S 
(starvation), D (DOX), D+R (DOX+ Rapa), D+S (DOX+ Starve) 
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3.4.2. Autophagy 
During the formation of autophagic vacuoles, LC3-I (14 kDa) is converted to LC3-II (16 kDa). 
Both LC3-I and LC3-II were measured and a ratio of LC3-II: LC3-I was used as a marker 
autophagy. Protein levels were measured against stain-free total protein. The LC3-II: LC3-I 
ratio was analysed. A significant decrease in autophagy was observed in the DOX group 
(0.3733± 0.0683, p> 0.01) compared to the control group (1.1420± 0.2262). There was also a 
decrease in the DOX+ Rapa (0.4344± 0.0543, p> 0.05) and DOX+ starve (0.4818± 0.1240, p> 
0.05) compared to the control group. There are significant differences between groups, but 
none relevant to this study. 
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Figure 3.7: LC3 protein expression. Values expressed in arbitrary units as mean ± SEM. (**p<0.01), 
(#p<0.05), ($p<0.05), (n=3-5). Representative western blot bands for each group. Abbreviation: C 
(control), R (rapamycin), S (starvation), D (DOX), D+R (DOX+ Rapa), D+S (DOX+ Starve) 
14 kDa 
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Chapter 4: Discussion and Conclusion 
 
This study investigated a potential treatment for attenuating the harmful effects associated with 
DOX administration in vivo. As previously mentioned, chronic cardiotoxicity is dose-
dependent, irreversible and linked with an unfavourable outcomes for affected patients. 
Moreover, when this condition ensues, the affected patients are no longer on chemotherapy and 
thus begs the question: what happens from the time a patient completes chemotherapy to the 
time when the cardiovascular complications becomes evident? Based on this question it is clear 
to see how difficult, if not impossible, it is to simulate this condition in pre-clinical models.  
Due to the complexity and life-threatening nature of the chronic form of cardiotoxicity, not 
only is it necessary to understand the molecular mechanisms involved, it is also necessary to 
identify potential adjuvant therapies. While cell culture experiments are simple to execute, they 
do not effectively mimic what is observed in cancer survivors; and it is for this reason that it is 
necessary to establish clinically relevant animal models. An interesting observation made in 
the literature is that the majority of in vivo studies published to date have utilized supra-
physiological concentrations of DOX in the acute setting and thus caution should be made 
when interpreting the results. Herman & Ferrans (1998) indicated that the use of smaller doses 
of DOX administered over an extended period of time in animals is more clinically relevant, 
and better simulates the myocardial alterations associated with chronic cardiotoxicity. The 
cumulative dose (total dose used for duration of study) used by the above indicated authors 
was 15 mg/kg for rats, administered over a couple of weeks. However, in mouse models (Table 
1.4 and Table 1.5), cumulative doses range from 12.5 – 90 mg/kg. Guided by the above 
information, a cumulative dose of 16 mg/kg DOX (2 mg/kg over eight weeks) was administered 
to mice in this study due to the fact that it is amongst the lower dosage range which induces 
cardiotoxicity, and therefore mimics the low dosages given to humans in an attempt to avoid 
cardiotoxicity. Furthermore, this concentration falls within the clinical range of 60 - 75 mg/m2 
that is administered to humans (human equivalent dose) (Desai et al, 2013). 
Autophagic activity in the heart has long being viewed as paradoxical; either being beneficial 
in one context and detrimental in another, all of which depends on the type (Matsui et al, 2007) 
and duration (Kang et al, 2008; Loos et al, 2011) of the stress, injury, and levels of autophagic 
activity (Eisenberg-Lerner et al, 2009) at the time. Considering that autophagy is additionally 
complemented by other forms of cell death such as apoptosis, it is challenging to ascertain 
whether it is pro-survival or pro-death. As such, this cross-talk between autophagy and 
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apoptosis has since been differentiated into three categories, namely: autophagy and apoptosis 
can stimulate cell death synergistically, or autophagy can promote survival by inhibiting 
apoptosis, or autophagy can allow apoptosis to occur alone without death caused by autophagy 
(Eisenberg-Lerner et al, 2009).  
This study has demonstrated that DOX treatment significantly downregulated autophagic 
activity when compared to the control (Figure 3.7). Although the exact mechanism by which 
DOX inhibits autophagy is yet to be discovered, other studies have suggested that DOX inhibits 
AMPK and ULK1 activity (autophagy promoters), and increases mTOR activity (autophagy 
inhibitor) (Kawaguchi et al, 2012; Park et al, 2016). While our results agree with the literature, 
it is important to note that the duration, dose, frequency of treatment, as well as the model 
simulated in this study is different in many aspects to that observed in the literature (Table 1.4 
and Table 1.5). This studies pre-treatment protocol, with either rapamycin or starvation, did 
not appear to attenuate autophagic downregulation in the DOX combination groups. This may 
be due to a number of reasons. Firstly, since rapamycin was administered to the experimental 
animals 30 minutes prior to DOX, this may not have been sufficient time to upregulate 
autophagy maximally to counteract the potent inhibitory actions of DOX on autophagy. 
Furthermore, since the half-life of rapamycin is indicated to be 58 – 63 hours (Nalbandian et 
al, 2015) and that of DOX is 17.7 hours in rodents (Rahman et al, 1986), the timing of the 
termination of the study did influence the results obtained as both the effects of the drugs at the 
time of termination have declined. Secondly, starvation, a potent mechanism used to stimulate 
autophagy, was induced 24 hours prior to DOX. Once DOX was administered, the animals 
were free to access food ad libitum. This return of nutrients thus returned autophagy to basal 
levels, however due the presence of DOX, the inhibitory action of this chemotherapeutic agent 
took over. Thirdly, since this study was terminated a week after the last injections and by this 
time the animals had access to food, the levels of autophagy detected in this study are only 
reflective of the levels of autophagy at that point in time. 
Myocardial apoptosis and oxidative stress are commonly cited characteristics of DOX-induced 
cardiotoxicity (Kumar et al, 2001; Kobayashi et al, 2010). This observation is supported by 
others (Shan et al, 1996; Kang et al, 2001; Arola et al, 2000) who have implicated the 
involvement of both the intrinsic and extrinsic apoptotic pathways of apoptosis and elevated 
oxidative stress levels after DOX treatment. This study however did not definitively 
demonstrate apoptosis induction (Figure 3.6) or changes in the oxidative stress parameters 
analysed (Table 3.2 and Table 3.3). This was rather surprising considering the overwhelming 
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amount of literature available regarding their roles in this context. In the presence of ROS, 
GSH is oxidized to GSSG, changing the ratio of GSH to GSSG. Even though this imbalance 
may be indicative of oxidative stress, this change is time-dependent as GSSG is eventually 
reduced back to GSH. The time of sample collection thus becomes an important factor when 
evaluating changes in glutathione. Similar to our results, Deng et al (2015) showed no changes 
in glutathione levels 72 hours after a single 15 mg/kg bolus administration of DOX despite 
other markers of oxidative damage being evident. Interestingly, Zhang et al (2015) illustrated 
significant changes in the GSH:GSSG ratio 48 hours but not after two weeks following weekly 
DOX doses of 2 mg/kg over five weeks.  
In contrast to the GSH:GSSG ratio which measures oxidative stress indirectly by evaluating 
the anti-oxidant status, CDs are markers of lipid peroxidation which is indicative of oxidative 
damage. Lipid peroxidation is the result of ROS removing a hydrogen atom from a fatty acid 
chain (usually polyunsaturated fatty acids), generating unpaired electrons. The fatty acid 
undergoes rearrangement which results in two double bonds being separated by a single bond, 
i.e. a conjugated diene (John Betteridge, 2000). It is not uncommon to detect no significant 
changes in CDs even if lipid peroxidation has occurred. CDs are formed in the early stages of 
lipid peroxidation and in time will undergo further changes. Malondialdehyde (MDA) is the 
end product of the peroxidative decomposition of polyunsaturated fatty acids and is thus 
considered a late marker of lipid peroxidation. In the context of DOX toxicity, Nowak et al 
(1995) demonstrated peak CD levels in the heart after 24 hours compared to MDA levels that 
peaked after 48 hours. A similar observation was made by Murin et al (2001) where CD levels 
peaked between 2 - 24 hours and declined by 48 hours, while MDA levels remained elevated 
throughout these time points in an ischemia/reperfusion model. Together, these studies suggest 
that while elevated levels of ROS may have occurred, a state of oxidative stress induced, 
ultimately resulting in oxidative damage. The ratio of GSG:GSSG and CD analysis may not be 
the most sensitive indicators of oxidative stress after 48 hours of an intervention as redox 
homeostasis is restored. The above may also explain why no changes in apoptotic activity was 
observed in this study considering that apoptosis is triggered as a direct consequence to DOX-
induced oxidative stress. 
Oxidative stress and inflammation cannot be easily separated as both conditions can influence 
one another. Inflammation which leads to fibrosis is an additional factor known to contribute 
to DOX-induced cardiotoxicity. Usually, fibrosis encompasses homeostasis, inflammation, 
proliferation and finally remodelling (Diegelmann & Evans, 2004). In the course of 
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homeostasis and inflammation, macrophages and neutrophils are recruited by particular 
cytokines to the injury site where they activate resident fibroblasts. Through the proliferation 
of these fibroblasts, they deposit collagen which occupies and replaces apoptotic 
cardiomyocytes (Khan & Sheppard, 2006). The tissue damage that occurs and the resulting 
inflammation that ensues increases ROS, which in turn enhances the release of fibrotic factors. 
Fibrosis is thus an important component of the repair process; however its accumulation can 
result in organ dysfunction, and eventually failure over time. This study noted significant 
fibrosis in the DOX group and significantly less fibrosis in the group that was starved prior to 
DOX administration (Figure 3.4), suggesting a potentially protective effect of starvation, 
despite the lack of autophagic attenuation. The histological changes associated with DOX 
treatment in this study not only consisted of fibrosis, but also a loss of cardiomyocyte area 
(Figure 3.2) as indicated by Šimůnek et al (2004). The reduction is cardiomyocyte area in the 
DOX treated group is indicative of protein degradation via the ubiquitin proteasome pathway 
(UPP), a major proteolytic pathway responsible for intracellular protein degradation (Gruene 
et al, 2004), since autophagy in this group was downregulated. Ubiquitination refers to the 
process of conjugation between free ubiquitin (Ub) and a substrate protein. Ub, a highly 
conserved molecule ubiquitously expressed in all eukaryotes, covalently attaches to targeted 
proteins in linear chains involving three enzymes: Ub-activating enzymes (E1), Ub-
conjugating enzymes (E2) and Ub-ligases (E3) which recognize a specific substrate and thus 
transfers the activated Ub molecule to a lysine residue of that specific substrate (Willis & 
Patterson, 2006; Patterson et al, 2007; Powell, 2006). Substrates marked in a poly-ubiquitin 
manner at lysine 48, results in the substrate being targeted for proteasomal degradation. In 
catabolic states where proteolysis is prominent, specific E3 ligases, Muscle Ring Finger-1 
(MuRF-1) and atrogin1/MAFbx (Muscle Atrophy F-box) are upregulated in a forkhead box 
(FoxO)-dependent manner (Bodine et al, 2001), and therefore regulate the ubiquitination of 
cardiomyocyte proteins for subsequent degradation (de Palma et al, 2008). However, the 
observed reduction in cardiomyocyte area in the DOX group did not impact on the overall 
myocardial weight (Table 3.1). 
It is possible that the induction of proteasomal specific ubiquitination contributed to the overall 
weight loss observed (Figure 3.1). It may also be a result of differences in food consumed 
(Table A1, Appendix A). It was not possible to statistically asses if there were differences in 
amount of food consumed so this too is just speculation. Further research is however required 
to confirm either of these statements in this model of prolonged DOX treatment. 
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In conclusion, the present study investigated the therapeutic potential of elevated autophagy 
using a pharmacological (rapamycin) and a physiological (starvation) approach, in an attempt 
to reduce the cardiac side effects associated with DOX treatment. Although the model utilized 
is unique and displayed some characteristics of DOX cardiotoxicity; mainly physical (body 
weight) and structural (cardiomyocyte area and cardiac fibrosis), the biochemical 
characteristics (oxidative stress and apoptosis) measured produced inconclusive results. These 
results may imply that biochemical changes are transient or that structural modifications take 
place before biochemical changes occur. Therefore, no definitive conclusions can be drawn on 
the precise effects and mechanisms of action of these therapeutic intervention within this 
scenario and further investigation is necessary. 
 
Limitations and Future Recommendations 
 
Like other studies, this study has its limitations and can be improved on going forward. While 
numerous limitations and future recommendations can be made, only a few will be listed, 
focused on and discussed. 
Greater sample size 
A major limitation of this model was the relatively small sample size (n = 6-7 per group). As 
each animal is unique, their responses to the same stimuli differs, and thus creates variability 
in the data collected. A larger sample size attenuates this variability allowing for greater 
statistical accuracy. A greater sample size would also be an advantage in this study due to the 
choice of rodent model utilized and the number of experiments performed. A mouse heart is 
much smaller than a rat heart, and in this case, some experiments were performed with a sample 
size of n = 3-4 per group. 
Additional time points 
Considering that the majority of data collected in this study was taken at the end of the 
treatment protocol and the experiments performed reflected this time point, it is likely that the 
early changes induced by DOX and/or autophagy upregulation may have been missed. 
Therefore, by adding earlier time points in to this study, we would be able to determine the 
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extent of biochemical alterations and whether they lead to structural modifications over the 
duration of the treatment protocol. 
Evaluation of cardiac function 
A decline in cardiac function (particularly LVEF), changes in heart rate and blood pressure, 
and abnormal ECG alterations are all signs of DOX toxicity. Due to the lack of cardiac function 
data, the model of DOX-induced cardiotoxicity was not fully validated. Further studies should 
thus include measurements of cardiovascular function either through echocardiography, 
working heart or Langendorff perfusions; and cardiovascular markers of damage such as 
cardiac troponins. 
Other considerations 
The measuring of inflammatory markers (e.g.: c-reactive protein and pro-inflammatory 
cytokines) to complement the fibrotic data and asses the inflammatory state of disease. 
The measuring of markers of autophagy (e.g.: p62, AMPK, mTOR) and apoptosis (e.g.: cleaved 
poly adenosine diphosphate-ribose polymerase (PARP), cytochrome c) would add value to this 
study as these would be able to indicate whether our intervention was sufficient to elevate 
autophagy. 
Multiple measurements of antioxidant activity, oxidative damage and oxidative status to fully 
understand the level of oxidative stress in myocardium across the different groups. Bearing in 
mind the timing of sample collection. 
A group with an autophagic inhibitor should be included to act as a negative control. This will 
allow for a more comprehensive assessment of the role of autophagy in this context. 
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Appendix A 
 
 
Table A1: Food consumed in grams 
 
 
Table A2: Animal mass over time in grams 
  
 
Control Rapamycin Starvation DOX DOX+ rapa Dox+ starve  
Week 1 x x x x x x 
Week 2 139.43 169.14 144.52 155.34 144.45 143.60 
Week 3 164.25 152.93 124.40 175.44 159.80 154.18 
Week 4 185.93 167.18 124.50 173.72 153.33 179.99 
Week 5 181.73 164.40 123.00 180.31 157.27 170.51 
Week 6 197.25 167.55 135.90 181.85 153.59 201.54 
Week 7 198.68 159.00 138.00 177.42 152.57 172.55 
Week 8 236.03 200.63 148.00 191.36 165.00 205.45 
Week 9 225.98 204.45 152.10 182.44 156.60 177.68 
Week 10 213.45 195.53 136.50 174.36 150.47 169.78 
 
 
Control Rapamycin Starvation DOX DOX+ rapa Dox+ starve  
Week 1 Mean 21.1000 19.3000 19.2667 19.5333 20.5500 20.1500 
 SEM 0.7257 1.4615 1.5720 0.6380 0.9588 0.8530 
Week 2 Mean 23.2167 21.2833 20.0667 21.8167 23.2167 22.5167 
 SEM 0.7355 1.7772 2.0816 0.7030 0.8460 0.9581 
Week 3 Mean 25.0000 22.3667 20.7000 22.9167 22.9167 23.1833 
 SEM 0.7685 2.0013 2.2802 0.7562 0.7562 1.0717 
Week 4 Mean 26.2333 22.9833 21.2167 23.8167 23.6167 23.9167 
 SEM 0.7584 2.0816 2.3034 0.8590 0.8717 1.1620 
Week 5 Mean 27.3833 24.1167 22.3833 24.4333 24.2000 24.5500 
 SEM 0.7609 2.1388 2.1425 0.8395 0.9441 1.3061 
Week 6 Mean 28.3000 24.8167 22.9167 24.5000 24.3500 24.8333 
 SEM 0.7971 2.0905 2.2470 0.8983 0.9081 1.2820 
Week 7 Mean 28.7167 25.8000 23.6167 24.5500 24.7167 24.4500 
 SEM 0.6353 1.8826 2.2261 0.7782 0.9245 1.1316 
Week 8 Mean 29.4833 26.9333 24.0667 24.9167 25.2333 25.4333 
 SEM 0.8203 1.7046 2.2917 0.7818 1.0415 1.2843 
Week 9 Mean 30.1667 28.0000 24.7167 24.9667 25.5833 25.1833 
 SEM 0.8119 1.8857 2.1499 0.7533 1.1256 1.1698 
Week 10 Mean 30.4167 28.0000 24.8167 25.3833 25.5667 25.5000 
 SEM 0.6630 1.8834 2.2279 0.8874 1.1659 1.1922 
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Table A3: Organ mass in grams 
 
 
Table A4: Various muscle mass in grams 
 
 
 
Control Rapamycin Starvation DOX DOX+ rapa Dox+ starve  
Heart  Mean 0.1845 0.1683 0.1275 0.1693 0.1452 0.1527 
 SEM 0.0253 0.0199 0.0179 0.0144 0.0123 0.0146 
Liver  Mean 1.5883 1.4118 1.1608 1.3070 1.3379 1.3290 
 SEM 0.0837 0.1208 0.1180 0.0455 0.0876 0.0543 
Pancreas Mean 0.2358 0.2877 0.3248 0.2993 0.3097 0.2997 
 SEM 0.0303 0.0388 0.0568 0.0129 0.0395 0.0191 
Kidney  Mean 0.1963 0.2340 0.1673 0.1543 0.1675 0.1760 
(right) SEM 0.0140 0.0560 0.0141 0.0067 0.0086 0.0054 
Kidney  Mean 0.2047 0.1908 0.1663 0.1743 0.1785 0.1755 
(left) SEM 0.0120 0.0173 0.0121 0.0062 0.0069 0.0077 
 
 
Control Rapamycin Starvation DOX DOX+ rapa Dox+ starve  
gastrocnemius  Mean 0.1385 0.1300 0.1213 0.1258 0.1440 0.1277 
(right) SEM 0.0119 0.0146 0.0113 0.0078 0.0084 0.0121 
gastrocnemius  Mean 0.1298 0.1292 0.1240 0.1272 0.1270 0.1283 
(left) SEM 0.0154 0.0092 0.0147 0.0086 0.0061 0.0107 
soleus Mean 0.0117 0.0086 0.0075 0.0098 0.0085 0.0065 
(right) SEM 0.0009 0.0022 0.0010 0.0016 0.0015 0.0010 
soleus Mean 0.0114 0.0105 0.0097 0.0075 0.0083 0.0088 
(left) SEM 0.0028 0.0017 0.0016 0.0019 0.0018 0.0011 
plantaris  Mean 0.0116 0.0063 0.0098 0.0112 0.0120 0.0090 
(right) SEM 0.0037 0.0014 0.0035 0.0019 0.0021 0.0023 
plantaris Mean 0.0143 0.0087 0.0077 0.0087 0.0115 0.0120 
(left) SEM 0.0032 0.0027 0.0027 0.0020 0.0022 0.0023 
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Figure A1: Caspase 3 total protein and bands detected. Left: Total protein. Right: Bands visualised. 
Rows (from left to right); C, R, S, D, D+ R, D+S, C, R, S, D, D+ R, D+S, D, D+ R. 
Figure A2: LC3 total protein and bands detected. Left: Total protein. Right: Bands visualised, top 
band 16kDa LC3I, bottom band 14kDa LC3II. Rows (from left to right); C, R, S, D, D+ R, D+S, C, 
R, S, D, D+ R, D+S, D, D+ R. 
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Appendix B 
 
Full protocols used during this study: 
Animal work 
The in vivo study was conducted on a total of 39 male black 6 (C57BL/6) mice. The study 
however was staggered. Mice were received after weaning at 3 weeks. Initially 20 mice were 
received from the Research Animal Facility, Faculty of Health Sciences, University of Cape 
Town and Animal Unit, Stellenbosch University, Tygerberg Campus. Overlapping the first 
study 20 more mice were received. Mice were left to acclimatise to the animal house at the 
University of Stellenbosch in the cages in which they arrived. The mice were kept on a 12-hour 
day- night cycle, fed a standard rodent chow (LabChef, Rodent Breeder) and given free access 
to food and water.  
Mice were then randomly split into groups; control, rapamycin, starvation, doxorubicin, dox- 
rapa combination and dox- starve combination groups respectively. The rats were left for 3 
weeks to acclimatize within their respective group. During this acclimation period 1 mouse 
died, prior to receiving any treatment. The total amount of animals per group were as followed: 
Control  6 
Rapamycin  6 
Starvation  6 
Doxorubicin  7 
Dox- Rapa  7 
Dox- Starve  7  
24 hours before the treatment the animals were weighed, food was taken from the starvation 
and the dox and starve groups at this time point. The average weight of the group was used to 
calculate the dosage.  
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The control group each received a 200µL injection of saline solution, administered via 
intraperitoneal injection. The rapamycin group received 2mg/kg of rapamycin solution (LKT 
laboratories, R0161), made up to a volume of 200µL, administered via intraperitoneal injection. 
The doxorubicin group received 2mg/kg of doxorubicin hydrochloride (LKT laboratories 
D5794) solution, made up to a volume of 200µL, administered via intraperitoneal injection. 
The dox- rapa combination group received 2mg/kg of rapamycin solution, made up to a volume 
of 200µL, administered via intraperitoneal injection then 30 minutes later, 2mg/kg of 
doxorubicin solution, made up to a volume of 200µL, also administered via intraperitoneal 
injection. The dox- starve combination group received 2mg/kg of doxorubicin solution, made 
up to a volume of 200µL, 24 hours after food was withheld, administered via intraperitoneal 
injection. The food was restored to the starvation group and the dox- starve group after 24 
hours. These treatment protocols continued for a total of 8 weeks, no animals were lost as a 
result of treatment. All injections were done using a new 29G x ½” 1mL insulin syringe. A 
week after the final treatment the animals were euthanized via cervical dislocation. Following 
euthanasia, the chest was opened, and the heart harvested. The removal of the heart was 
necessary for the study as well as serving as confirmation of death. Hearts were sectioned 
coronally, roughly in half. One section was flash frozen in liquid nitrogen, then stored at -80°C. 
The other section was preserved in a 4% buffered formaldehyde (approximately 10% formalin) 
solution. 
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Staining 
Staining was performed on the tissue preserved in formaldehyde. 
Tissue processing 
Tissue processing was done automatically using a Tissue-Tek II tissue processor, using the 
following protocol: 
Dehydration 
1. 70% alcohol  1.5 hrs 
2. 70% alcohol   1.5 hrs 
3. 90% alcohol   1.5 hrs 
4. 95% alcohol   1.5 hrs 
5. 95% alcohol   1.5 hrs 
6. 100% alcohol   1.5 hrs 
7. 100% alcohol   1.5 hrs 
8. 100% alcohol   2 hrs 
Clearing 
9. Xylene   1.5 hrs 
10. Xylene   2 hrs 
Impregnation  
11. Paraffin wax   2 hrs 
12. Paraffin wax   2 hrs 
Total time    20 hrs 
Paraffin wax was purchased from Sigma- Aldrich (P3558 Paraplast). 
Embedding 
After processing the tissue was embedded in paraffin wax. Embedding was done using a Leica 
EG1150 H paraffin embedding station. 
Sectioning 
The tissue was sectioned using a Lecia RM 2125 RT microtome, at a 2º angle and 5µM 
thickness. 3 serial sections were taken for each sample. These sections were transferred to a 
Stellenbosch University  https://scholar.sun.ac.za
62 
 
water bath ±40ºC then picked up onto a glass slide then placed in a 65ºC oven for roughly 5 
minutes. 
Staining 
Staining was performed at the University of Stellenbosch Medical Campus, Tygerberg. 
Haematoxylin and eosin staining was done automatically using a Leica ST5010 Autostainer 
XL, using the following protocol: 
1. Xylene    5 minutes 
2. Xylene    5 minutes 
3. 99% alcohol   2 minutes 
4. 99% alcohol   2 minutes 
5. 96% alcohol    2 minutes 
6. 70% alcohol    2 minutes 
7. Tap water   2 minutes 
8. Haematoxylin   8 minutes 
9. Running water  5 minutes 
10. Eosin    4 minutes 
11. Running water  1 minutes 
12. 70% alcohol   30 seconds 
13. 96% alcohol   30 seconds 
14. 96% alcohol   30 seconds 
15. 99% alcohol   30 seconds 
16. Xylene    1 minutes 
Total time     41 minutes 
After staining allow slides to dry then mount cover slip with DPX. 
Picrosirius red staining was done by hand, using the following protocol: 
1. Xylene    5 minutes 
2. Xylene    5 minutes 
3. 99% alcohol   2 minutes 
4. 99% alcohol   2 minutes 
5. 96% alcohol    2 minutes 
6. 70% alcohol    2 minutes 
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7. Tap water   2 minutes 
8. Weigert’s haematoxylin 12 minutes 
9. Running tap water  10 minutes 
10. Picrosirius red   60 minutes 
11. Acidified water   2 minutes 
12. Acidified water  2 minutes 
13. 100% alcohol   5 dips 
14. 100% alcohol   5 dips 
15. 100% alcohol   5 dips 
16. Xylene    1 minutes 
17. Xylene    2 minutes 
Total time    ± 110 minutes 
After staining allow slides to dry then mount cover slip with DPX. 
Sections were analysed using a Nikon Eclipse E4000 microscope and NIS Elements imaging 
software (version 4.10).  
Haematoxylin and eosin stains were photographed at 40x using a Nikon DS-Fi2 camera. These 
micrographs were stitched together using the NIS Elements to create an image of the entire 
organ. This whole image was used to assess any major structural abnormalities.  
Picrosirius red sections were photographed at 400x, random areas were photographed. Each 
group had 15 random images taken. The images were analysed using ImageJ software (version 
1.49) using the following protocol: 
1. File- Open        [ctrl + O] 
2. Image- Adjust.  
Brightness/ Contrast      [ctrl + Shift + C] 
Set- Set Display Range.  
Adjust minimum and maximum display values to clarify image 
3. Image- Adjust.  
Threshold       [ctrl + Shift + T] 
Adjust hue, saturation and brightness to select entire tissue (red and yellow) 
4. Analyse- Measure       [ctrl + M] 
This measurement is the Total Tissue Area 
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5. Image- Adjust.  
Threshold       [ctrl + Shift + T] 
Adjust hue, saturation and brightness to select red tissue only 
6. Analyse- Measure       [ctrl + M] 
This measurement is the Red Tissue Area 
This method measures the area of the red stain rather than the colour intensity to calculate 
fibrosis. Fibrosis was calculated as such: 
𝑅𝑒𝑑 𝑇𝑖𝑠𝑠𝑢𝑒 𝐴𝑟𝑒𝑎
𝑇𝑜𝑡𝑎𝑙 𝑇𝑖𝑠𝑠𝑢𝑒 𝐴𝑟𝑒𝑎
× 100 = 𝐹𝑖𝑏𝑟𝑜𝑢𝑠 % 
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Oxidative stress 
Fluorometry was performed on some of the frozen tissue. These assays were performed at the 
Oxidative Stress Research Centre, Cape Peninsula University of Technology, Bellville. Lysates 
were prepared for the oxidative stress fluorometric assay according to the following protocol: 
1. Defrost frozen tissue slowly by placing on ice 
2. Tissue was weighed and placed into a labelled Eppendorf tube  
a. 15mg for GSH and CDs 
b. 10mg for GSSG 
3. To GSH add phosphate buffer (1000µl per 100mg tissue) 
For 15mg add 150µl 
4. To GSSG add 1% M2VP phosphate buffer solution (1000µl per 100mg) 
For 10mg add 100µl 
5. Homogenise tissue 
6. Wait for froth to settle (±30 minutes) 
7. Centrifuge at 12 000rpm for 10 minutes 
8. Transfer supernatant into a new Eppendorf tube (discard pellet) 
These lysates were used for the GSH, GSSG and CDs assays. The lysates may be stored at -
80ºC and used at a later stage. After pilot testing a dilution factor of 20 was calculated 
appropriate. The GSH/ GSSG assay was performed using the following protocol: 
1. Load the appropriate amount of GSH standard solution (3µM GSH) into the first wells 
of a 96-well plate (in triplicate) 
2. Load the appropriate amount of phosphate buffer solution into the corresponding wells 
of the plate 
 Blank 1 2 3 4 5 
Standard solution (µL) 0 167 333 500 667 833 
Phosphate buffer (µL) 1000 833 667 500 333 167 
Concentration 0 0,5 1,0 1,5 2,0 2,5 
 
3. Load 50µL of sample to the wells of a 96-well plate (in triplicate) 
4. Load 50µL DTNB to each well using multichannel pipette  
5. Load 50µL glutathione reductase to each well using multichannel pipette 
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6. Load 50µL NADPH to each well as quickly as possible to each well using multichannel 
pipette 
7. Measure absorbance at 412nm every 30 seconds for 3 minutes using a Fluoroskan 
Ascent Microplate Fluorometer (Thermo Fisher Scientific) 
Absorbance readings were analysed, Microsoft Excel was used to average triplicates and 
GraphPad Prism (version 6.01) was used to generate a standard curve. The time of 
measurement was plotted on the X axis and the absorbance of each standard was plotted on the 
Y axis of a line graph. Linear regression was used to calculate the slope of each standard. This 
was used to generate the standard curve; the concentration of each standard was plotted on the 
X axis and the slope of each standard was plotted on the Y axis of a line graph. Linear 
regression was used to calculate the slope of the standard curve. 
To calculate the concentration of each sample a slope must be generated for each sample. The 
time of measurement was plotted on the X axis and the absorbance of each sample was plotted 
on the Y axis of a line graph. Linear regression was used to calculate the slope of each sample. 
The slope was used as the Y, the M and C were taken from the standard curve allowing as to 
calculate the X by rearranging the formula for a straight line. 
𝑌 = 𝑀𝑋 + 𝐶 
𝑌 − 𝐶
𝑀
= 𝑋 
This however is the concentration in µM. To convert the unit to µM/g, the concentration (µM) 
must be multiplied by the dilution factor and the volume of the sample (L) and divided by the 
weight of tissue (g).  
𝜇𝑀 𝑔⁄ = 𝜇𝑀 × 𝐷𝐹 × 𝐿 𝑔⁄  
The above calculation is for GSH. To calculate GSSH simply divide the answer by 2. 
𝜇𝑀 𝑔⁄ = 𝜇𝑀 × 𝐷𝐹 × 𝐿 𝑔⁄  ÷ 2 
To perform the conjugated dienes (CDs) assay, lysates from the GSH group were modified 
according to the following protocol: 
1. Add 300µL chloroform and 600µL methanol together to form a solution 
2. Add 250µL of this solution to 50µL of lysate sample in an Eppendorf tube 
3. Invert Eppendorf tube to mix 
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4. Centrifuge at 14 000rpm for 1minutes 
5. Pipette 200µL of the bottom layer of liquid into a new Eppendorf tube 
6. Leave tubes open, refrigerate overnight (±12 hours) at 4ºC  
7. Add 1mL cyclohexane to each Eppendorf tube, vortex for 20s 
8. Load 300µL blank into the wells of a UV clear 96-well plate (in triplicate) 
8. Load 300µL of each sample into the wells (in triplicate) 
9. Measure absorbance at 380nm using a Fluoroskan Ascent Microplate Fluorometer 
(Thermo Fisher Scientific) 
Absorbance readings were analysed, Microsoft Excel was used to average triplicates. For the 
CD’s there is no standard curve. The concentration was calculated by dividing absorbance by 
the excitation coefficient. 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
(𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘)
𝑒𝑥𝑐𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑒𝑐𝑒𝑛𝑡 (29500)
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Western blot 
Western blots were performed on some of the frozen tissue.  
Lysates were prepared for the western blot assays according to the following protocol: 
1. Defrost frozen tissue slowly by placing on ice 
2. Tissue was weighed and placed into a labelled Eppendorf tube 
a. 10-15mg 
3. Add 100µL of working RIPA buffer to each Eppendorf tube 
a. 100µL per 10mg 
b. 100µL per 15mg preferred 
4. Homogenize tissue on ice 
a. Rinse homogenizer with distilled H₂O, then working RIPA buffer 
5. Wait roughly an hour for froth to settle 
6. Centrifuge at 4ºC at 14 000rpm for 15minutes 
7. Remove supernatant into new Eppendorf tube 
8. Centrifuge at 4ºC at 14 000rpm for 15minutes 
9. Remove supernatant into new Eppendorf tube 
10. Pipette 2ul of RIPA buffer on a Direct Detect Spectrometer assay free card as the blank 
11. Pipette 2ul of each sample onto the cards 
a. Select protein 
b. Select RIPA calibration curveq3 
12. Measure protein concentration on Direct Detect Spectrometer 
a. Using that value, the sample protein concentration (X), the following can be 
calculated: 
b. The amount of sample needed to prepare 30µg of protein per lysate: 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝜇𝐿 = (30 × 1000) ÷  (𝑋) × 1000 
c. The amount of working RIPA buffer to be added: 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝜇𝐿 = 10 − [(30 × 1000) ÷  (𝑋) × 1000] 
13. Prepare lysate to a total volume of 20µL by adding: 
a. Amount of sample to prepare 30µg of protein, calculated by the equation above 
b. Amount of working RIPA, calculated by equation the above 
c. 15µL of Laemmli’s buffer 
14. Once all lysates are prepared, boil each for 5minutes at 95°C 
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15. Store lysates at -80ºC 
Western blots were run according to the following protocol: 
1. Take lysates out freezer 
a. Thaw on ice 
2. Boil lysates for 5minutes at 95˚C 
3. Centrifuge at 9300 RPM  
4. Place back on ice 
5. Place the assembly in a gel tank 
a. Fill the buffer dam with cold 1x running buffer until it spills into the tank 
b. Top up the tank until the buffer is level with the buffer at the top of the dam (the 
dam is the empty area between the two gel plates, if running 2 gels or between 
the one plate and the buffer dam plate, when only 1 gel is being run) 
6. Wash the wells with running buffer, using an insulin syringe. 
7. Load wells [15 well can take max 26ul] 
a. Load 3µl of protein marker to the first lane on the far left of each gel 
b. Load 13.34µl lysate per well to ensure 20µg protein per lane 
8. Run gels  
9. Place the green lid with appropriate leads  
a. Black to black: red to red 
b. Connect to the power pack 
c. 100V, 400mA for ±3 hours 
10. Switch off power and disconnect electrodes. Remove gel plates from the tank and 
proceed to electro transfer step immediately 
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Transferring to membrane 
1. Use trans-blot turbo RTA transfer kit 
a. Soak blotting paper in transfer buffer 
b. Soak membrane in methanol for a few seconds then 
c. Soak membrane in transfer buffer for ±5 minutes 
2. Activate on chemidoc 
3. Place in trans-blot turbo transfer system cassestte 
4. Transfer on mmw for 7 minutes 
5. Image on chemidoc 
6. Rinse membrane on shaker 
a. 3x 5 minutes stripping buffer 
7. Block for 2 hours in 5% milk on shaker 
8. Place in 50mL tube containing 5mL of primary antibody 
a. Leave on rotator in 4ºC walk in fridge for 72 hours 
9. Remove membrane from primary antibody 
10. Rinse membrane in 1x TBS-T 
11. Place in secondary antibody 
a. Leave on rotator at room temperature for 1 hour 
12. Rinse membrane in TBS-T 
13. In foil covered tube, prepare ECL in 1:1 ratio (0.5ul: 0.5ul = per membrane) 
14. Pour ECL over membrane, focusing on MW area of protein 
a. Incubate for 5 minutes 
15. Image 
a. Open “image lab” 
b. Select ‘blot’ then ‘chemi’ 
c. Do not overexpose protein of interest 
d. Image ladder to confirm molecular weight of protein 
e. Save images 
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Appendix C 
 
List of reagents used during this study: 
Animal work 
1. Doxorubicin 
2. Rapamycin 
1. Doxorubicin was prepared as such: 
• 10mg dry powder was dissolved in 5mL of saline solution and vortexed until the 
powder was fully dissolved. 
• This solution was further diluted by adding an additional 20mL of saline solution. 
Bringing the total volume to 25mL and the concentration to 400µg/mL. 
400𝜇𝑔 𝑚𝐿⁄ = 2000𝜇𝑔 5𝑚𝐿⁄  
2𝑚𝑔 5𝑚𝐿⁄ = 2000𝜇𝑔 5𝑚𝐿⁄  
As each animal receives 2mg/kg 
2𝑚𝑔 5𝑚𝐿 𝑎𝑛𝑑 2𝑚𝑔 𝑘𝑔⁄⁄ ∴  5𝑚𝐿 𝑘𝑔⁄  
5𝑚𝐿 𝑘𝑔 =  5𝑢𝐿 𝑔⁄⁄  
Therefore, the equation to calculate dose would be as follows: 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑔𝑟𝑎𝑚 × 5𝑢𝐿 = 𝑑𝑜𝑠𝑒 𝑝𝑒𝑟 𝑎𝑛𝑖𝑚𝑎𝑙 
𝑑𝑜𝑠𝑒 𝑝𝑒𝑟 𝑎𝑛𝑖𝑚𝑎𝑙 × (𝑛 + 1) = 𝑡𝑜𝑡𝑎𝑙 𝑑𝑜𝑠𝑒 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 
(𝑛 + 1) × 200𝑢𝐿 − 𝑡𝑜𝑡𝑎𝑙 𝑑𝑜𝑠𝑒 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 = 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑖𝑙𝑢𝑒𝑛𝑡 
(n + 1) is used to prepare an extra dose in case of emergency 
200µL is used as the total injection volume 
If, for example, the average weight of the group containing 4 mice is 21.6 grams then: 
21.6𝑔 × 5𝜇𝐿 = 108𝑢𝐿 
108𝜇𝑙 × 6 = 648𝑢𝐿 
1200𝑢𝐿 − 648𝑢𝐿 = 552𝑢𝐿 
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648µL of doxorubicin solution was mixed with 552µL of saline solution. Each mouse then 
received 200µL of this solution. 
2. Rapamycin was prepared as such: 
• 10mg dry powder was dissolved 2mL of 70% alcohol and vortexed until the powder 
was fully dissolved, 23mL of saline solution was also added. Bringing the total volume 
to 25mL and the concentration to 400µg/mL. The rapamycin solutions were then 
prepared in the same manner as the doxorubicin solutions. 
 
Oxidative stress 
The solutions required for the assays: 
1. Phosphate buffer (75mM) 
2. NADPH (1mM) in phosphate buffer 
3. M2VP (30mM) in 0.1M HCl 
4. DTNB (0.3mM) in phosphate buffer 
5. Glutathione reductase (16 µL in 984 µL phosphate buffer) 
 
1. Phosphate buffer was prepared as such: 
• 1st solution 
• 1,035g Sodium phosphate monobasic monohydrate (NaH2PO4·H2O) in 100ml of 
distilled H2O and mix until dissolved. 
• 2nd solution 
• 1,335g di-Sodium hydrogen phosphate anhydrous (Na2HPO4) in 100ml of 
distilled H2O and mix until dissolved. 
• Mix 18ml of the 1st solution with 82ml of the 2nd solution. 
• Adjust pH to pH 7.5 
• Store at 4ºC  
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Western blot 
The solutions required for the preparation of the lysates for the western blot assay: 
1. Working RIPA buffer 
2. Laemmli’s buffer 
 
1. To prepare working RIPA: 
• Add 1mL RIPA buffer to an Eppendorf tube  
• Add 42ul Protease Cocktail 
• Add 10ul PMSF   
• Add 5ul NaF   
• Add 5ul Sodium Orthovandate (Na3VO4) 
• Vortex to mix and keep on ice during use 
 
To prepare RIPA buffer: 
• Add 790 mg Tris base to 75 ml dH2O.  
• Add 900 mg NaCl and stir solution until all solids are dissolved. 
o Using HCl, adjust pH to 7.4 
• Add 10 ml of 10 % NP-40 to solution  
• Add 2.5 ml of 10 % Na-deoxycholate and stir until solution is clear  
• Add 1 ml of 100 mM EDTA to the solution. 
• Adjust the volume of solution to 100 ml using a graduated cylinder 
To prepare the RIPA reagents: 
10 % NP-40          
• Dissolve 1g NP-40 powder into 10 ml dH2O in a foil wrapped flask 
• Place a stirrer in beaker and place beaker on heated magnetic stirrer until powder is 
completely dissolved 
10% Na-deoxycholate         
• Dissolve 0.5g Na-deoxycholate powder into 5 ml dH2O 
100 mM EDTA         
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• 404.47g/1000ml = 1M = 1000mM 
o 40.447g/1000ml =100mM 
• Therefore 20.22g/500ml =100mM 
• Make up to 400ml, adjust pH to pH7.4 
• Adjust to 500ml 
2. To prepare Laemmli’s buffer: 
• Add 850ul Laemmli’s stock solution to a foil wrapped flask 
• Add 150ul 2-Mercaptoethanol in fume hood 
To prepare the Laemmli’s stock: 
• Add 38ml distilled H2O to a foil wrapped flask 
• Add 10ml 0.5M Tris 
o use HCl to adjust pH to pH6.8 
• Add 8ml glycerol 
• Add 16ml 10% SDS 
• Add 4ml 0.05% (w/v) Bromophenol blue 
To prepare the Laemmli’s stock reagents: 
0.5M Tris 
• Add 6.057g of Tris to 70ml distilled H2O 
o adjust pH to pH6.8 
• Make up to 100ml 
10% SDS 
• Add 2g SDS to 20ml distilled H2O 
0.05% (w/v) Bromophenol blue 
• Add 2,5mg bromophenol to 5ml distilled H2O 
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The solutions required for the preparation of the lysates for the western blot assay: 
1. Resolving gel 
2. Stacking gel 
3. Running buffer 
4. Transfer buffer  
5. TBST 
 
1. 12% resolving gel (2 gels) 
• To a small beaker 
o Add 5.7mL distilled H2O 
o Add 4.5mL 40% acrylamide solution 
o Add 3.75mL 1.5M Tris-HCl (pH8.8) 
o Add 150µL 10% w/v SDS 
o Add 75µL TCE 
• Swirl gently to mix 
o Add 150µL 10% w/v APS 
• Swirl gently to mix 
o Add 6µL of TEMED 
• Swirl gently to mix 
• Using a plastic Pasteur pipette quickly pour between to plates, pour from one corner to 
avoid bubble, leaving space for stacking gel 
• Top with a layer of EtOH 
• Allow gel to set  
o 30-60 minutes 
• Once gel has set, pour off EtOH, dab dry with blotting paper 
2. 4% stacking gel (2 gels) 
• To a small beaker 
o Add 4.48mL distilled H2O 
o Add 1mL 40% acrylamide solution 
o Add 2mL 0.5M Tris-HCl (pH6.8) 
o Add 80µL 10% w/v SDS 
• Swirl gently to mix 
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o Add 80µL 10% w/v APS 
• Swirl gently to mix 
o Add 8µL of TEMED 
• Swirl gently to mix 
• Using a plastic Pasteur pipette quickly pour between to plates, pour from one corner to 
avoid bubble, leaving space for comb. 
• Insert comb gently, pushing down and avoiding bubble formation  
• Allow gel to set  
 
3. Running buffer 
• 100ml 10x running buffer 
• 900ml dH20 
10x running buffer  
• 60.6g Tris 
• 288g Glycine 
• Dissolve Tris and Glycine in 1.5L dH20 (±1 hr) 
o Adjust pH to pH8.6 
• Add 20g SDS 
• Add dH2O until 2L 
 
4. Transfer buffer  
• 200ml 5x transfer buffer 
• 200ml ethanol  
• 600ml dH20 
 
5. TBS-T 
• 100ml 10x TBS 
• 900ml dH20 
• 1ml of tween   
10x TBS:  
• 24.g Tris 
• 80g NaCl 
• Dissolve in 600ml dH20 
o Adjust pH to pH7.6 
• Make up to 1L 
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Table C1: List of Equipment used. 
Equipment Company   Catalogue #  Country   City  
ChemiDoc XRS+ 
system 
Biorad 170-8265 South 
Africa 
Sandton 
Direct Detect card Merck DDAC00010-GR USA Massachusetts 
Direct Detect 
Spectrometer  
Merck DDHW00010-
WW 
USA Massachusetts 
Fluoroskan Ascent 
Microplate 
Fluorometer  
Thermo 
Fisher 
51119200 USA Massachusetts 
Leica Autostainer 
XL automated 
staining machine  
Lecia 
biosystems 
ST5010  Germany Wetzlar 
Leica microtome Lecia 
biosystems 
RM 2125 RT Germany Wetzlar 
Leica paraffin 
embedding station. 
Lecia 
biosystems 
EG1150 H  Germany Wetzlar 
Tissu-Tek II tissue 
processor 
Sakura 
Finetechnical 
4634 Japan Tokyo 
low-fluorescence 
polyvinylidene 
fluoride (LF PVDF) 
Biorad 162-0174 South 
Africa 
Sandton 
Mini-Protean Tetra 
Cell 
Biorad 165-8004 China Shanghai 
Nikon camera Nikon DS-Fi2  Japan Tokyo 
Nikon Eclipse 
microscope  
Nikon E4000 Japan Tokyo 
Polytron 
homogenizer  
Kinematica PT 2100 Switzerland Lucerne 
Powerpac 300 Biorad 165-5051 China Shanghai 
Trans-Blot Turbo 
Transfer System 
Biorad 170-4155 China Shanghai 
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Table C2: List of reagents used. 
Reagent Company  Catalogue # Country   City  
10 % Na-
deoxycholate  
Sigma- 
Aldrich 
D6750 New 
Zealand 
Auckland 
10 % NP-40  Sigma- 
Aldrich 
74385 Switzerland Buchs 
10% SDS Sigma- 
Aldrich 
L3771 Japan Tokyo 
2-Mercaptoethanol  Biorad 161-0710 China Shanghai 
40% acrylamide 
solution 
Merck 1.00640.1000 Germany Darmstadt 
Alcohol  Ilovo .500 South Africa Merebank 
APS Sigma- 
Aldrich 
A3678 Japan Tokyo 
BLUeye 
Prestained Protein 
Ladder 
GeneDireX PM007-0500 China Beijing 
Bromophenol blue Merck SAAR1437500LB South Africa Modderfontein 
Chloroform  Merck 102444 USA Massachusetts 
Clarity ECL 
substrate  
Biorad 170-5061 South Africa Sandton 
Cover slips  Lasec GLAS2C9M2250REC South Africa Cape Town 
Cyclohexane   Merck 102822 USA Massachusetts 
di-Sodium 
hydrogen 
phosphate 
anhydrous 
(Na2HPO4) 
Sigma- 
Aldrich 
S3139 Switzerland Buchs 
doxorubicin 
hydrochloride  
LKT 
laboratories 
D5794 USA St Paul 
DPX Sigma- 
Aldrich 
6522 Spain Madrid 
DTNB Sigma- 
Aldrich 
D21820 USA St Louis 
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EDTA Sigma- 
Aldrich 
EDS Germany Steinheim 
Eosin Lecia 
microsystems 
3801600E England Peterborough 
Formaldehyde  Merck 1.04003.25000 Germany Darmstadt 
Glutathione 
reductase  
Sigma- 
Aldrich 
G3664 USA St Louis 
Glycerol  Merck SAAR2676520LC South Africa Modderfontein 
Glycine Sigma- 
Aldrich 
G8898 China Shanghai 
GSH standard Sigma- 
Aldrich 
G4251 USA St Louis 
Haematoxylin Sigma- 
Aldrich 
MHS16 USA St Louis 
HCl Merck SAAR3063040LP South Africa Modderfontein 
M2VP Sigma- 
Aldrich 
69701 USA St Louis 
methanol Merck 1.06009.2500 Germany Darmstadt 
NaCl Merck 1.06404.0500 Denmark Hellerup 
NADPH  Sigma- 
Aldrich 
N6758 USA St Louis 
NaF Merck 1.93270.0500 India Mumbai 
Paraffin wax  Sigma- 
Aldrich 
P3558 USA St Louis 
Picrosirius red Sigma- 
Aldrich 
365548 USA St Louis 
PMSF  Sigma- 
Aldrich 
93482 Switzerland Buchs 
Protease Cocktail Roche 11873580001 Switzerland Basel 
Rapamycin   LKT 
laboratories 
R0161 USA St Paul 
Slides  Lasec GLAS4S22M3000F South Africa Cape Town 
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Sodium 
Orthovandate 
(Na3VO4) 
Sigma- 
Aldrich 
s6508 India Karnataka 
Sodium phosphate 
diabasic 
Sigma- 
Aldrich 
S3264 USA St Louis 
Sodium phosphate 
monobasic 
monohydrate 
(NaH2PO4·H2O)  
Sigma- 
Aldrich 
S8282 USA St Louis 
TCE Sigma- 
Aldrich 
J54801 Japan Tokyo 
TEMED Sigma- 
Aldrich 
T9281 China Shanghai 
Transfer buffer Biorad 10026938 USA Hercules 
Tris base  Merck 648310 China Shanghai 
Tween20 Sigma- 
Aldrich 
P1379 USA St Louis 
Xylene  Merck 1.08633.4000 Germany Darmstadt 
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